{"id":42742,"date":"2021-11-29T14:29:04","date_gmt":"2021-11-29T13:29:04","guid":{"rendered":"https:\/\/www.crct-inserm.fr\/?page_id=42742"},"modified":"2024-01-08T12:05:57","modified_gmt":"2024-01-08T11:05:57","slug":"impact_en","status":"publish","type":"page","link":"https:\/\/www.crct-inserm.fr\/en\/impact_en\/","title":{"rendered":"ImPact_en"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”a00720d8-8e3f-4b20-83b7-6d54485f541c” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”694d3d5d-3e0a-4cd1-b2ba-4eea0d99d5b4″ background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/09\/Imagepageequipecordelier.png” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”8292df69-9d3c-4423-ab4f-a4755f6c1135″ width_tablet=”85%” width_phone=”95%” width_last_edited=”on|phone” custom_padding_last_edited=”off|desktop” global_colors_info=”{}”]<\/p>\n

Team
Pierre Cordelier<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ header_2_font=”Open Sans||||||||” global_colors_info=”{}”]<\/p>\n

ImPact : <\/strong><\/h2>\n

Therapeutic innovation in pancreatic cancer<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” width=”50%” disabled=”on” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/LOGO-TOUCAN-Horizontal.png” title_text=”LOGO-TOUCAN-Horizontal” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font_size=”22px” global_colors_info=”{}”]<\/p>\n

Le laboratoire d\u2019Excellence Toulouse Cancer est un projet qui vise \u00e0 comprendre les m\u00e9canismes de r\u00e9sistance et de rechute dans les cancers.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”rgba(43,135,218,0) 50%|#f2efef 50%” background_color_gradient_start=”rgba(43,135,218,0)” background_color_gradient_start_position=”50%” background_color_gradient_end=”#f2efef” background_color_gradient_end_position=”0%” custom_padding=”0px|||||” disabled=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=FkQuawiGWUw” image_src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/video.jpg” _builder_version=”4.16″ _module_preset=”default” width=”80%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

The specificities<\/strong>
of our research axis<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Pancreatic cancer, or pancreatic adenocarcinoma (PDAC), will soon become the second leading cause of cancer deaths worldwide, due to late diagnosis and lack of effective treatment. Our research effort is dedicated to the development of new strategies to improve the management of patients with this cancer.<\/p>\n

In this context, our research objective is to better understand the mechanisms of PDAC oncogenesis and therapeutic resistance. In particular, we are studying the role of genome remodelling and replication in gene expression and resistance to DNA-breaking agents (Project 1). We are deciphering the proteins and protein-protein interactions involved in pancreatic oncogenesis and resistance to treatment using intracellular antibodies (Project 2). Finally, we are investigating the mechanisms responsible for the resistance of cancer cells to oncolytic viruses, and studying the impact of these viruses on the anti-tumour immune response (Project 3).<\/p>\n

The overall goal of this research project is to translate our basic research findings into tangible therapeutic innovations for pancreatic cancer patients, using a precision medicine approach.<\/p>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Pancreatic Cancer<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”5px||5px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Oncogenesis<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Resistance<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Innovative therapies<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Regulation of gene expression<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Protein-protein interaction<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Intracellular antibodies<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Oncolytic viruses<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Gene therapy<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Immunotherapy<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

interdisciplinarity<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

research<\/strong>
projects<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_blog fullwidth=”off” posts_number=”3″ include_categories=”265″ use_manual_excerpt=”off” show_more=”on” show_author=”off” show_date=”off” show_categories=”off” masonry_tile_background_color=”#f2efef” _builder_version=”4.16″ _module_preset=”default” header_level=”h3″ header_font=”|800|||||||” header_font_size=”20px” body_font_size=”20px” read_more_text_color=”#5EC7ED” read_more_font_size=”20px” read_more_line_height=”3em” background_enable_color=”off” border_width_all=”0px” global_colors_info=”{}”][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

THE TEAM’S
<\/strong>FOCUS<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”#ffffff 50%|rgba(174,227,246,0) 50%” background_color_gradient_overlays_image=”on” background_color_gradient_start=”#ffffff” background_color_gradient_start_position=”50%” background_color_gradient_end=”rgba(174,227,246,0)” background_color_gradient_end_position=”0%” background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/Filets-bleu-actu.png” background_size=”contain” background_position=”bottom_center” custom_padding=”0px|||||” saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” header_font_size_tablet=”” header_font_size_phone=”” header_font_size_last_edited=”on|desktop” header_2_font_size_tablet=”” header_2_font_size_phone=”” header_2_font_size_last_edited=”on|desktop” header_4_font_size_tablet=”” header_4_font_size_phone=”” header_4_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

Discover<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1000″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” _builder_version=”4.16″ _module_preset=”412cf9f9-c22e-468d-92e3-f93d454642a9″ header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_color_all_image=”#ffffff” border_width_bottom_image=”15px” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-3px||false|false” global_colors_info=”{}”]<\/p>\n

Understand<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1081,1218″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” show_image_tablet=”” show_image_phone=”” show_image_last_edited=”on|phone” disabled_on=”off|off|off” _builder_version=”4.21.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” global_colors_info=”{}”]<\/p>\n

Participate<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1321,1259″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” disabled_on=”off|off|off” _builder_version=”4.21.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

Live<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_code _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]\n\n

\n\t\n \n
\n \n
\n

\n CRCT-Oncopole<\/span>\n <\/span>\n Suivre<\/span>\n \n <\/path><\/svg>1,220<\/span>\n <\/path><\/svg>1,117<\/span>\n <\/span>\n <\/p>\n

\n Compte officiel du Centre de Recherches en Canc\u00e9rologie de Toulouse <\/p>\n <\/div>\n

\n
\n <\/path><\/svg> <\/div>\n \"crctoncopole\"\n <\/div>\n <\/a>\n<\/div>\n\n
\n \n
\n\n \n
\n
\n \n \"crctoncopole;\n <\/a>\n \n CRCT-Oncopole<\/a>\n @crctoncopole<\/a>\n \n \t\t ·<\/span>\n\t
\n 21 Ao\u00fbt 1693609681678217706<\/span><\/a>\n <\/div>\n <\/div>\n
\n <\/path><\/svg> <\/div>\n <\/div>\n\n
\n \t\t\t\t

Castelnau-Montratier c\u00e9l\u00e8bre la lutte contre le cancer. Jeudi 24 ao\u00fbt 2023 conf\u00e9rence avec Fr\u00e9d\u00e9ric Chibon responsable de l'\u00e9quipe @OncoSarc du @crctoncopole accompagn\u00e9 de Gwena\u00ebl Ferron et Martin Gauthier oncologue @IUCTOncopole
\nD\u00e9couvrir l'\u00e9quipe
\n\u27a1\ufe0fhttps:\/\/www.crct-inserm.fr\/oncosarc\/ <\/p>\n\t\t\t\t\t\t\n \n

\n \n \n <\/path><\/svg>
<\/path><\/svg><\/div>\n \n \"Image\n \n Image du flux Twitter.<\/span> <\/a>\n \n <\/div>\n\n\t \n \n <\/div>\n \n\t\n
\n \n <\/path><\/g><\/svg> R\u00e9pondre sur Twitter 1693609681678217706<\/span>\n <\/a>\n\n \n <\/path><\/svg> Retweeter sur Twitter 1693609681678217706<\/span>\n 0<\/span>\n <\/a>\n\n \n <\/path><\/g><\/svg> J\u2019aime sur Twitter 1693609681678217706<\/span>\n 6<\/span>\n <\/a>\n\n \n Twitter<\/span>\n 1693609681678217706<\/span>\n <\/a>\n \n\t<\/div>\n\n\t<\/div>\n\n <\/div>\n\n Voir plus<\/span><\/a>\n\n<\/span>\n<\/div>\n[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

scientific productions
<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”PUBLICATIONS 2024″ open=”on” open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t6BDVTCJV<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2024<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 42742<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-65aedf62ae84c4f7a79fded0ff9dd5b3%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22FNILSLDE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lumeau%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-31%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELumeau%2C%20Audrey%2C%20Nicolas%20Bery%2C%20Audrey%20Frances%2C%20Marion%20Gayral%2C%20Guillaume%20Labrousse%2C%20Cyril%20Ribeyre%2C%20Charl%26%23xE8%3Bne%20Lopez%2C%20et%20al.%20%26%23x201C%3BCytidine%20Deaminase%20Resolves%20Replicative%20Stress%20and%20Protects%20Pancreatic%20Cancer%20from%20DNA-Targeting%20Drugs.%26%23x201D%3B%20%3Ci%3ECancer%20Research%3C%5C%2Fi%3E%2C%20January%2031%2C%202024.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-22-3219%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-22-3219%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cytidine%20deaminase%20resolves%20replicative%20stress%20and%20protects%20pancreatic%20cancer%20from%20DNA-targeting%20drugs%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Lumeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Bery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Frances%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Gayral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Labrousse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Ribeyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charl%5Cu00e8ne%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ad%5Cu00e8le%22%2C%22lastName%22%3A%22Nevot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdessamad%22%2C%22lastName%22%3A%22El%20Kaoutari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naima%22%2C%22lastName%22%3A%22Hanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Sarot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Perrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Pablo%22%2C%22lastName%22%3A%22Cerapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Madrid-Mencia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%22%2C%22lastName%22%3A%22Pancaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Jeanne%22%2C%22lastName%22%3A%22Pillaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Bergoglio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Torrisani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelson%22%2C%22lastName%22%3A%22Dusetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Hoffmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malik%22%2C%22lastName%22%3A%22Lutzmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%5D%2C%22abstractNote%22%3A%22Cytidine%20deaminase%20%28CDA%29%20functions%20in%20the%20pyrimidine%20salvage%20pathway%20for%20DNA%20and%20RNA%20synthesis%20and%20has%20been%20shown%20to%20protect%20cancer%20cells%20from%20deoxycytidine-based%20chemotherapies.%20In%20this%20study%2C%20we%20observed%20that%20CDA%20was%20overexpressed%20in%20pancreatic%20adenocarcinoma%20from%20patients%20at%20baseline%20and%20was%20essential%20for%20experimental%20tumor%20growth.%20Mechanistic%20investigations%20revealed%20that%20CDA%20localized%20to%20replication%20forks%20where%20it%20increased%20replication%20speed%2C%20improved%20replication%20fork%20restart%20efficiency%2C%20reduced%20endogenous%20replication%20stress%2C%20minimized%20DNA%20breaks%2C%20and%20regulated%20genetic%20stability%20during%20DNA%20replication.%20In%20cellular%20pancreatic%20cancer%20models%2C%20high%20CDA%20expression%20correlated%20with%20resistance%20to%20DNA-damaging%20agents.%20Silencing%20CDA%20in%20patient-derived%20primary%20cultures%20in%20vitro%20and%20in%20orthotopic%20xenografts%20in%20vivo%20increased%20replication%20stress%20and%20sensitized%20pancreatic%20adenocarcinoma%20cells%20to%20oxaliplatin.%20This%20study%20sheds%20light%20on%20the%20role%20of%20CDA%20in%20pancreatic%20adenocarcinoma%2C%20offering%20insights%20into%20how%20this%20tumor%20type%20modulates%20replication%20stress.%20These%20findings%20suggest%20that%20CDA%20expression%20could%20potentially%20predict%20therapeutic%20efficacy%20and%20that%20targeting%20CDA%20induces%20intolerable%20levels%20of%20replication%20stress%20in%20cancer%20cells%2C%20particularly%20when%20combined%20with%20DNA-targeted%20therapies.%22%2C%22date%22%3A%222024-01-31%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F0008-5472.CAN-22-3219%22%2C%22ISSN%22%3A%221538-7445%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%2C%226FNA338P%22%5D%2C%22dateModified%22%3A%222024-04-11T14%3A30%3A23Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Lumeau, Audrey, Nicolas Bery, Audrey Frances, Marion Gayral, Guillaume Labrousse, Cyril Ribeyre, Charlène Lopez, et al. “Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs.” Cancer Research<\/i>, January 31, 2024. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-3219<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2023″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t6BDVTCJV<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2023<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 42742<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-f6d6825862773d4b5e8534fd9ca25e05%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%229PXGSXZV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Keyan%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKeyan%2C%20Kripa%20S.%2C%20Safa%20Salim%2C%20Swetha%20Gowda%2C%20Doua%20Abdelrahman%2C%20Syeda%20Sakina%20Amir%2C%20Zeyaul%20Islam%2C%20Claire%20Vargas%2C%20et%20al.%20%26%23x201C%3BControl%20of%20TGF%26%23x3B2%3B%20Signalling%20by%20Ubiquitination%20Independent%20Function%20of%20E3%20Ubiquitin%20Ligase%20TRIP12.%26%23x201D%3B%20%3Ci%3ECell%20Death%20%26amp%3B%20Disease%3C%5C%2Fi%3E%2014%2C%20no.%2010%20%28October%2020%2C%202023%29%3A%20692.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41419-023-06215-y%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41419-023-06215-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Control%20of%20TGF%5Cu03b2%20signalling%20by%20ubiquitination%20independent%20function%20of%20E3%20ubiquitin%20ligase%20TRIP12%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kripa%20S.%22%2C%22lastName%22%3A%22Keyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Safa%22%2C%22lastName%22%3A%22Salim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Swetha%22%2C%22lastName%22%3A%22Gowda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doua%22%2C%22lastName%22%3A%22Abdelrahman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Syeda%20Sakina%22%2C%22lastName%22%3A%22Amir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zeyaul%22%2C%22lastName%22%3A%22Islam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Vargas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Teresa%22%2C%22lastName%22%3A%22Bengoechea-Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amira%22%2C%22lastName%22%3A%22Alwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subrat%22%2C%22lastName%22%3A%22Dahal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prasanna%20R.%22%2C%22lastName%22%3A%22Kolatkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sahar%22%2C%22lastName%22%3A%22Da%27as%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Torrisani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Ericsson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farhan%22%2C%22lastName%22%3A%22Mohammad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omar%20M.%22%2C%22lastName%22%3A%22Khan%22%7D%5D%2C%22abstractNote%22%3A%22Transforming%20growth%20factor%20%5Cu03b2%20%28TGF%5Cu03b2%29%20pathway%20is%20a%20master%20regulator%20of%20cell%20proliferation%2C%20differentiation%2C%20and%20death.%20Deregulation%20of%20TGF%5Cu03b2%20signalling%20is%20well%20established%20in%20several%20human%20diseases%20including%20autoimmune%20disorders%20and%20cancer.%20Thus%2C%20understanding%20molecular%20pathways%20governing%20TGF%5Cu03b2%20signalling%20may%20help%20better%20understand%20the%20underlying%20causes%20of%20some%20of%20those%20conditions.%20Here%2C%20we%20show%20that%20a%20HECT%20domain%20E3%20ubiquitin%20ligase%20TRIP12%20controls%20TGF%5Cu03b2%20signalling%20in%20multiple%20models.%20Interestingly%2C%20TRIP12%20control%20of%20TGF%5Cu03b2%20signalling%20is%20completely%20independent%20of%20its%20E3%20ubiquitin%20ligase%20activity.%20Instead%2C%20TRIP12%20recruits%20SMURF2%20to%20SMAD4%2C%20which%20is%20most%20likely%20responsible%20for%20inhibitory%20monoubiquitination%20of%20SMAD4%2C%20since%20SMAD4%20monoubiquitination%20and%20its%20interaction%20with%20SMURF2%20were%20dramatically%20downregulated%20in%20TRIP12-%5C%2F-%20cells.%20Additionally%2C%20genetic%20inhibition%20of%20TRIP12%20in%20human%20and%20murine%20cells%20leads%20to%20robust%20activation%20of%20TGF%5Cu03b2%20signalling%20which%20was%20rescued%20by%20re-introducing%20wildtype%20TRIP12%20or%20a%20catalytically%20inactive%20C1959A%20mutant.%20Importantly%2C%20TRIP12%20control%20of%20TGF%5Cu03b2%20signalling%20is%20evolutionary%20conserved.%20Indeed%2C%20genetic%20inhibition%20of%20Drosophila%20TRIP12%20orthologue%2C%20ctrip%2C%20in%20gut%20leads%20to%20a%20reduced%20number%20of%20intestinal%20stem%20cells%20which%20was%20compensated%20by%20the%20increase%20in%20differentiated%20enteroendocrine%20cells.%20These%20effects%20were%20completely%20normalised%20in%20Drosophila%20strain%20where%20ctrip%20was%20co-inhibited%20together%20with%20Drosophila%20SMAD4%20orthologue%2C%20Medea.%20Similarly%2C%20in%20murine%203D%20intestinal%20organoids%2C%20CRISPR%5C%2FCas9%20mediated%20genetic%20targeting%20of%20Trip12%20enhances%20TGF%5Cu03b2%20mediated%20proliferation%20arrest%20and%20cell%20death.%20Finally%2C%20CRISPR%5C%2FCas9%20mediated%20genetic%20targeting%20of%20TRIP12%20in%20MDA-MB-231%20breast%20cancer%20cells%20enhances%20the%20TGF%5Cu03b2%20induced%20migratory%20capacity%20of%20these%20cells%20which%20was%20rescued%20to%20the%20wildtype%20level%20by%20re-introducing%20wildtype%20TRIP12.%20Our%20work%20establishes%20TRIP12%20as%20an%20evolutionary%20conserved%20modulator%20of%20TGF%5Cu03b2%20signalling%20in%20health%20and%20disease.%22%2C%22date%22%3A%222023-10-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41419-023-06215-y%22%2C%22ISSN%22%3A%222041-4889%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222023-11-06T09%3A04%3A42Z%22%7D%7D%2C%7B%22key%22%3A%226P4GQGUW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Barbey%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBarbey%2C%20Odile%2C%20Hubert%20Lulka%2C%20Naima%20Hanoun%2C%20Hafid%20Belhadj-Tahar%2C%20Fabienne%20Vernejoul%2C%20Gilles%20Cambois%2C%20Mich%26%23xE8%3Ble%20Tiraby%2C%20Louis%20Buscail%2C%20Fabian%20Gross%2C%20and%20Pierre%20Cordelier.%20%26%23x201C%3BPreclinical%20Development%20of%20Non-Viral%20Gene%20Therapy%20for%20Patients%20with%20Advanced%20Pancreatic%20Cancer.%26%23x201D%3B%20%3Ci%3EMolecular%20Therapy.%20Methods%20%26amp%3B%20Clinical%20Development%3C%5C%2Fi%3E%2029%20%28June%208%2C%202023%29%3A%20162%26%23x2013%3B72.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.omtm.2023.03.005%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.omtm.2023.03.005%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preclinical%20development%20of%20non-viral%20gene%20therapy%20for%20patients%20with%20advanced%20pancreatic%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Barbey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Lulka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naima%22%2C%22lastName%22%3A%22Hanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hafid%22%2C%22lastName%22%3A%22Belhadj-Tahar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Vernejoul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Cambois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mich%5Cu00e8le%22%2C%22lastName%22%3A%22Tiraby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabian%22%2C%22lastName%22%3A%22Gross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%5D%2C%22abstractNote%22%3A%22Pancreatic%20cancer%20remains%20one%20of%20the%20greatest%20challenges%20in%20oncology%20for%20which%20therapeutic%20intervention%20is%20urgently%20needed.%20We%20previously%20demonstrated%20that%20the%20intra-tumoral%20gene%20transfer%20of%20somatostatin%20receptor%202%2C%20to%20combat%20tumor%20aggressiveness%2C%20or%20of%20deoxycytidine%20kinase%20and%20uridylate%20monophosphate%20kinase%2C%20to%20sensitize%20to%20gemcitabine%20chemotherapy%2C%20has%20anti-tumoral%20potential%20in%20experimental%20models%20of%20cancer.%20Here%2C%20we%20describe%20the%20development%20of%20the%20CYL-02%20non-viral%20gene%20therapy%20product%20that%20comprises%20a%20DNA-plasmid%20encoding%20for%20the%20three%20aforementioned%20genes%2C%20which%20expression%20is%20targeted%20to%20tumor%20cells%2C%20and%20complexed%20with%20polyethyleneimine%20non-viral%20vector.%20We%20performed%20pre-clinical%20toxicology%2C%20bio-distribution%2C%20and%20therapeutic%20activity%20studies%20of%20CYL-02%20in%20two%20rodent%20models%20of%20pancreatic%20cancer.%20We%20found%20that%20CYL-02%20is%20safe%2C%20does%20not%20increase%20gemcitabine%20toxicity%2C%20is%20rapidly%20cleared%20from%20blood%20following%20intravenous%20administration%2C%20and%20sequestered%20in%20tumors%20following%20intra-tumoral%20injection.%20CYL-02%20drives%20the%20expression%20of%20therapeutic%20genes%20in%20cancer%20cells%20and%20strongly%20sensitizes%20tumor%20cells%20to%20gemcitabine%2C%20both%20in%5Cu00a0vitro%20and%20in%5Cu00a0vivo%2C%20with%20significant%20inhibition%20of%20tumor%20cells%20dissemination.%20This%20study%20was%20instrumental%20for%20the%20later%20use%20of%20CYL-02%20in%20patients%20with%20advanced%20pancreatic%20cancer%2C%20demonstrating%20that%20rigorous%20and%20thorough%20preclinical%20investigations%20are%20informative%20for%20the%20clinical%20transfer%20of%20gene%20therapies%20against%20this%20disease.%22%2C%22date%22%3A%222023-06-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.omtm.2023.03.005%22%2C%22ISSN%22%3A%222329-0501%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222023-04-18T13%3A20%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22C4UP9SYS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Cosquer%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-26%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Cosquer%2C%20Guillaume%2C%20Charlotte%20Maulat%2C%20Barbara%20Bournet%2C%20Pierre%20Cordelier%2C%20Etienne%20Buscail%2C%20and%20Louis%20Buscail.%20%26%23x201C%3BPancreatic%20Cancer%20in%20Chronic%20Pancreatitis%3A%20Pathogenesis%20and%20Diagnostic%20Approach.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2015%2C%20no.%203%20%28January%2026%2C%202023%29%3A%20761.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15030761%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15030761%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pancreatic%20Cancer%20in%20Chronic%20Pancreatitis%3A%20Pathogenesis%20and%20Diagnostic%20Approach%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Le%20Cosquer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Maulat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%5D%2C%22abstractNote%22%3A%22Chronic%20pancreatitis%20is%20one%20of%20the%20main%20risk%20factors%20for%20pancreatic%20cancer%2C%20but%20it%20is%20a%20rare%20event.%20Inflammation%20and%20oncogenes%20work%20hand%20in%20hand%20as%20key%20promoters%20of%20this%20disease.%20Tobacco%20is%20another%20co-factor.%20During%20alcoholic%20chronic%20pancreatitis%2C%20the%20cumulative%20risk%20of%20cancer%20is%20estimated%20at%204%25%20after%2015%20to%2020%20years.%20This%20cumulative%20risk%20is%20higher%20in%20hereditary%20pancreatitis%3A%2019%20and%2012%25%20in%20the%20case%20of%20PRSS1%20and%20SPINK1%20mutations%2C%20respectively%2C%20at%20an%20age%20of%2060%20years.%20The%20diagnosis%20is%20difficult%20due%20to%3A%20%28i%29%20clinical%20symptoms%20of%20cancer%20shared%20with%20those%20of%20chronic%20pancreatitis%3B%20%28ii%29%20the%20parenchymal%20and%20ductal%20remodeling%20of%20chronic%20pancreatitis%20rendering%20imaging%20analysis%20difficult%3B%20and%20%28iii%29%20differential%20diagnoses%2C%20such%20as%20pseudo-tumorous%20chronic%20pancreatitis%20and%20paraduodenal%20pancreatitis.%20Nevertheless%2C%20the%20occurrence%20of%20cancer%20during%20chronic%20pancreatitis%20must%20be%20suspected%20in%20the%20case%20of%20back%20pain%2C%20weight%20loss%2C%20unbalanced%20diabetes%2C%20and%20jaundice%2C%20despite%20alcohol%20withdrawal.%20Imaging%20must%20be%20systematically%20reviewed.%20Endoscopic%20ultrasound-guided%20fine-needle%20biopsy%20can%20contribute%20by%20targeting%20suspicious%20tissue%20areas%20with%20the%20help%20of%20molecular%20biology%20%28search%20for%20KRAS%2C%20TP53%2C%20CDKN2A%2C%20DPC4%20mutations%29.%20Short-term%20follow-up%20of%20patients%20is%20necessary%20at%20the%20clinical%20and%20paraclinical%20levels%20to%20try%20to%20diagnose%20cancer%20at%20a%20surgically%20curable%20stage.%20Pancreatic%20surgery%20is%20sometimes%20necessary%20if%20there%20is%20any%20doubt.%22%2C%22date%22%3A%222023-01-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers15030761%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222024-01-08T14%3A48%3A37Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Keyan, Kripa S., Safa Salim, Swetha Gowda, Doua Abdelrahman, Syeda Sakina Amir, Zeyaul Islam, Claire Vargas, et al. “Control of TGFβ Signalling by Ubiquitination Independent Function of E3 Ubiquitin Ligase TRIP12.” Cell Death & Disease<\/i> 14, no. 10 (October 20, 2023): 692. https:\/\/doi.org\/10.1038\/s41419-023-06215-y<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Barbey, Odile, Hubert Lulka, Naima Hanoun, Hafid Belhadj-Tahar, Fabienne Vernejoul, Gilles Cambois, Michèle Tiraby, Louis Buscail, Fabian Gross, and Pierre Cordelier. “Preclinical Development of Non-Viral Gene Therapy for Patients with Advanced Pancreatic Cancer.” Molecular Therapy. Methods & Clinical Development<\/i> 29 (June 8, 2023): 162–72. https:\/\/doi.org\/10.1016\/j.omtm.2023.03.005<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Le Cosquer, Guillaume, Charlotte Maulat, Barbara Bournet, Pierre Cordelier, Etienne Buscail, and Louis Buscail. “Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach.” Cancers<\/i> 15, no. 3 (January 26, 2023): 761. https:\/\/doi.org\/10.3390\/cancers15030761<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2022″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.19.0″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t6BDVTCJV<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2022<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 42742<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-242d25f1b0bf98c8ceb2110c68a2466b%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22YRBDWUZS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Quillien%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-31%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EQuillien%2C%20Lorraine%2C%20Louis%20Buscail%2C%20and%20Pierre%20Cordelier.%20%26%23x201C%3BPancreatic%20Cancer%20Cell%20and%20Gene%20Biotherapies%3B%20Past%2C%20Present%20and%20Future.%26%23x201D%3B%20%3Ci%3EHuman%20Gene%20Therapy%3C%5C%2Fi%3E%2C%20December%2031%2C%202022.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fhum.2022.210%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fhum.2022.210%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pancreatic%20cancer%20cell%20and%20gene%20biotherapies%3B%20past%2C%20present%20and%20future%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorraine%22%2C%22lastName%22%3A%22Quillien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%5D%2C%22abstractNote%22%3A%22%3A%20Solid%20cancers%20remain%20a%20major%20health%20challenge%20in%20terms%20of%20research%2C%20not%20only%20due%20to%20their%20structure%20and%20organisation%20but%20also%20in%20the%20molecular%20and%20genetic%20variations%20present%20between%20tumours%20as%20well%20as%20within%20the%20same%20tumour.%20When%20adding%20on%20the%20tumour%20microenvironment%20with%20cancer-associated%20cells%2C%20vasculature%20and%20the%20body%27s%20immune%20response%20%28or%20lack%20of%29%2C%20the%20weapons%20used%20to%20tackle%20this%20disease%20must%20also%20be%20diverse%20and%20intricate.%20Developing%20gene-based%20therapies%20against%20tumours%20contributes%20to%20the%20diverse%20lines%20of%20attack%20already%20established%20for%20cancers%20and%20can%20potentially%20overcome%20certain%20obstacles%20encountered%20with%20these%20strategies%2C%20the%20lack%20of%20tumour%20selectivity%20with%20chemotherapies%20for%20example.%20Given%20the%20high%20mortality%20and%20relapse%20rate%20associated%20with%20pancreatic%20cancer%2C%20novel%20treatments%20including%20gene%20therapy%20are%20actively%20being%20investigated.%20Even%20though%20no%20gene%20therapies%20for%20PC%20are%20currently%20on%20the%20market%2C%20a%20significant%20amount%20of%20clinical%20trials%20are%20underway%20especially%20in%20active%20and%20recruiting%20or%20recently%20completed%20phases.%22%2C%22date%22%3A%222022-12-31%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2Fhum.2022.210%22%2C%22ISSN%22%3A%221557-7422%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222023-01-02T14%3A38%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22LIBD2KYU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chaves-Almagro%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-13%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChaves-Almagro%2C%20Carline%2C%20Johanna%20Auriau%2C%20Aliz%26%23xE9%3Be%20Dortignac%2C%20Pascal%20Clerc%2C%20Hubert%20Lulka%2C%20Simon%20Deleruyelle%2C%20Fabrice%20Projetti%2C%20et%20al.%20%26%23x201C%3BUpregulated%20Apelin%20Signaling%20in%20Pancreatic%20Cancer%20Activates%20Oncogenic%20Signaling%20Pathways%20to%20Promote%20Tumor%20Development.%26%23x201D%3B%20%3Ci%3EInternational%20Journal%20of%20Molecular%20Sciences%3C%5C%2Fi%3E%2023%2C%20no.%2018%20%28September%2013%2C%202022%29%3A%2010600.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms231810600%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms231810600%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Upregulated%20Apelin%20Signaling%20in%20Pancreatic%20Cancer%20Activates%20Oncogenic%20Signaling%20Pathways%20to%20Promote%20Tumor%20Development%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carline%22%2C%22lastName%22%3A%22Chaves-Almagro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanna%22%2C%22lastName%22%3A%22Auriau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aliz%5Cu00e9e%22%2C%22lastName%22%3A%22Dortignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Clerc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Lulka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Deleruyelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Projetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Nakhl%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Frances%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judit%22%2C%22lastName%22%3A%22Berta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Gigoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Fourmy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marl%5Cu00e8ne%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Guillermet-Guibert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Knibiehler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralf%22%2C%22lastName%22%3A%22Jockers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Valet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Audigier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Masri%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20decades%20of%20effort%20in%20understanding%20pancreatic%20ductal%20adenocarcinoma%20%28PDAC%29%2C%20there%20is%20still%20a%20lack%20of%20innovative%20targeted%20therapies%20for%20this%20devastating%20disease.%20Herein%2C%20we%20report%20the%20expression%20of%20apelin%20and%20its%20receptor%2C%20APJ%2C%20in%20human%20pancreatic%20adenocarcinoma%20and%20its%20protumoral%20function.%20Apelin%20and%20APJ%20protein%20expression%20in%20tumor%20tissues%20from%20patients%20with%20PDAC%20and%20their%20spatiotemporal%20pattern%20of%20expression%20in%20engineered%20mouse%20models%20of%20PDAC%20were%20investigated%20by%20immunohistochemistry.%20Apelin%20signaling%20function%20in%20tumor%20cells%20was%20characterized%20in%20pancreatic%20tumor%20cell%20lines%20by%20Western%20blot%20as%20well%20as%20proliferation%2C%20migration%20assays%20and%20in%20murine%20orthotopic%20xenograft%20experiments.%20In%20premalignant%20lesions%2C%20apelin%20was%20expressed%20in%20epithelial%20lesions%20whereas%20APJ%20was%20found%20in%20isolated%20cells%20tightly%20attached%20to%20premalignant%20lesions.%20However%2C%20in%20the%20invasive%20stage%2C%20apelin%20and%20APJ%20were%20co-expressed%20by%20tumor%20cells.%20In%20human%20tumor%20cells%2C%20apelin%20induced%20a%20long-lasting%20activation%20of%20PI3K%5C%2FAkt%2C%20upregulated%20%5Cu03b2-catenin%20and%20the%20oncogenes%20c-myc%20and%20cyclin%20D1%20and%20promoted%20proliferation%2C%20migration%20and%20glucose%20uptake.%20Apelin%20receptor%20blockades%20reduced%20cancer%20cell%20proliferation%20along%20with%20a%20reduction%20in%20pancreatic%20tumor%20burden.%20These%20findings%20identify%20the%20apelin%20signaling%20pathway%20as%20a%20new%20actor%20for%20PDAC%20development%20and%20a%20novel%20therapeutic%20target%20for%20this%20incurable%20disease.%22%2C%22date%22%3A%222022-09-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fijms231810600%22%2C%22ISSN%22%3A%221422-0067%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22PKLPPQDF%22%2C%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222022-09-26T08%3A26%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22EWH9LQYU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Keller%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-18%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKeller%2C%20Laura%2C%20Claudine%20Tardy%2C%20Laetitia%20Ligat%2C%20Soazig%20Le%20Pennec%2C%20Nicolas%20Bery%2C%20Faten%20Kora%26%23xEF%3Bchi%2C%20Patrick%20Chinestra%2C%20et%20al.%20%26%23x201C%3BTripartite%20Split-GFP%20Assay%20to%20Identify%20Selective%20Intracellular%20Nanobody%20That%20Suppresses%20GTPase%20RHOA%20Subfamily%20Downstream%20Signaling.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Immunology%3C%5C%2Fi%3E%2013%20%28August%2018%2C%202022%29%3A%20980539.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2022.980539%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2022.980539%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tripartite%20split-GFP%20assay%20to%20identify%20selective%20intracellular%20nanobody%20that%20suppresses%20GTPase%20RHOA%20subfamily%20downstream%20signaling%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudine%22%2C%22lastName%22%3A%22Tardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ligat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soazig%22%2C%22lastName%22%3A%22Le%20Pennec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Bery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faten%22%2C%22lastName%22%3A%22Kora%5Cu00efchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Chinestra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lissa%22%2C%22lastName%22%3A%22David%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9mi%22%2C%22lastName%22%3A%22Gence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Favre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Cabantous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Olichon%22%7D%5D%2C%22abstractNote%22%3A%22Strategies%20based%20on%20intracellular%20expression%20of%20artificial%20binding%20domains%20present%20several%20advantages%20over%20manipulating%20nucleic%20acid%20expression%20or%20the%20use%20of%20small%20molecule%20inhibitors.%20Intracellularly-functional%20nanobodies%20can%20be%20considered%20as%20promising%20macrodrugs%20to%20study%20key%20signaling%20pathways%20by%20interfering%20with%20protein-protein%20interactions.%20With%20the%20aim%20of%20studying%20the%20RAS-related%20small%20GTPase%20RHOA%20family%2C%20we%20previously%20isolated%2C%20from%20a%20synthetic%20phage%20display%20library%2C%20nanobodies%20selective%20towards%20the%20GTP-bound%20conformation%20of%20RHOA%20subfamily%20proteins%20that%20lack%20selectivity%20between%20the%20highly%20conserved%20RHOA-like%20and%20RAC%20subfamilies%20of%20GTPases.%20To%20identify%20RHOA%5C%2FROCK%20pathway%20inhibitory%20intracellular%20nanobodies%2C%20we%20implemented%20a%20stringent%2C%20subtractive%20phage%20display%20selection%20towards%20RHOA-GTP%20followed%20by%20a%20phenotypic%20screen%20based%20on%20F-actin%20fiber%20loss.%20Intracellular%20interaction%20and%20intracellular%20selectivity%20between%20RHOA%20and%20RAC1%20proteins%20was%20demonstrated%20by%20adapting%20the%20sensitive%20intracellular%20protein-protein%20interaction%20reporter%20based%20on%20the%20tripartite%20split-GFP%20method.%20This%20strategy%20led%20us%20to%20identify%20a%20functional%20intracellular%20nanobody%2C%20hereafter%20named%20RH28%2C%20that%20does%20not%20cross-react%20with%20the%20close%20RAC%20subfamily%20and%20blocks%5C%2Fdisrupts%20the%20RHOA%5C%2FROCK%20signaling%20pathway%20in%20several%20cell%20lines%20without%20further%20engineering%20or%20functionalization.%20We%20confirmed%20these%20results%20by%20showing%2C%20using%20SPR%20assays%2C%20the%20high%20specificity%20of%20the%20RH28%20nanobody%20towards%20the%20GTP-bound%20conformation%20of%20RHOA%20subfamily%20GTPases.%20In%20the%20metastatic%20melanoma%20cell%20line%20WM266-4%2C%20RH28%20expression%20triggered%20an%20elongated%20cellular%20phenotype%20associated%20with%20a%20loss%20of%20cellular%20contraction%20properties%2C%20demonstrating%20the%20efficient%20intracellular%20blocking%20of%20RHOA%5C%2FB%5C%2FC%20proteins%20downstream%20interactions%20without%20the%20need%20of%20manipulating%20endogenous%20gene%20expression.%20This%20work%20paves%20the%20way%20for%20future%20therapeutic%20strategies%20based%20on%20protein-protein%20interaction%20disruption%20with%20intracellular%20antibodies.%22%2C%22date%22%3A%222022-8-18%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2022.980539%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Farticles%5C%2F10.3389%5C%2Ffimmu.2022.980539%5C%2Ffull%22%2C%22collections%22%3A%5B%22W973EZ5X%22%2C%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222022-09-28T09%3A36%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22ITA74LF8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sorbara%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESorbara%2C%20Marie%2C%20Pierre%20Cordelier%2C%20and%20Nicolas%20Bery.%20%26%23x201C%3BAntibody-Based%20Approaches%20to%20Target%20Pancreatic%20Tumours.%26%23x201D%3B%20%3Ci%3EAntibodies%3C%5C%2Fi%3E%2011%2C%20no.%203%20%28July%2012%2C%202022%29%3A%2047.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fantib11030047%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fantib11030047%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Antibody-Based%20Approaches%20to%20Target%20Pancreatic%20Tumours%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Sorbara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Bery%22%7D%5D%2C%22abstractNote%22%3A%22Pancreatic%20cancer%20is%20an%20aggressive%20cancer%20with%20a%20dismal%20prognosis.%20This%20is%20due%20to%20the%20difficulty%20to%20detect%20the%20disease%20at%20an%20early%20and%20curable%20stage.%20In%20addition%2C%20only%20limited%20treatment%20options%20are%20available%2C%20and%20they%20are%20confronted%20by%20mechanisms%20of%20resistance.%20Monoclonal%20antibody%20%28mAb%29%20molecules%20are%20highly%20specific%20biologics%20that%20can%20be%20directly%20used%20as%20a%20blocking%20agent%20or%20modified%20to%20deliver%20a%20drug%20payload%20depending%20on%20the%20desired%20outcome.%20They%20are%20widely%20used%20to%20target%20extracellular%20proteins%2C%20but%20they%20can%20also%20be%20employed%20to%20inhibit%20intracellular%20proteins%2C%20such%20as%20oncoproteins.%20While%20mAbs%20are%20a%20class%20of%20therapeutics%20that%20have%20been%20successfully%20employed%20to%20treat%20many%20cancers%2C%20they%20have%20shown%20only%20limited%20efficacy%20in%20pancreatic%20cancer%20as%20a%20monotherapy%20so%20far.%20In%20this%20review%2C%20we%20will%20discuss%20the%20challenges%2C%20opportunities%20and%20hopes%20to%20use%20mAbs%20for%20pancreatic%20cancer%20treatment%2C%20diagnostics%20and%20imagery.%22%2C%22date%22%3A%222022-07-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fantib11030047%22%2C%22ISSN%22%3A%222073-4468%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2073-4468%5C%2F11%5C%2F3%5C%2F47%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222022-09-28T09%3A35%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22S9T9RFPA%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cordelier%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-10%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECordelier%2C%20Pierre%2C%20Manon%20Costa%2C%20and%20J%26%23xE9%3Br%26%23xF4%3Bme%20Fehrenbach.%20%26%23x201C%3BSlow-Fast%20Model%20and%20Therapy%20Optimization%20for%20Oncolytic%20Treatment%20of%20Tumors.%26%23x201D%3B%20%3Ci%3EBulletin%20of%20Mathematical%20Biology%3C%5C%2Fi%3E%2084%2C%20no.%206%20%28May%2010%2C%202022%29%3A%2064.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11538-022-01025-3%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11538-022-01025-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Slow-Fast%20Model%20and%20Therapy%20Optimization%20for%20Oncolytic%20Treatment%20of%20Tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Fehrenbach%22%7D%5D%2C%22abstractNote%22%3A%22The%20present%20work%20studies%20models%20of%20oncolytic%20virotherapy%20without%20space%20variable%20in%20which%20virus%20replication%20occurs%20at%20a%20faster%20time%20scale%20than%20tumor%20growth.%20We%20address%20the%20questions%20of%20the%20modeling%20of%20virus%20injection%20in%20this%20slow-fast%20system%20and%20of%20the%20optimal%20timing%20for%20different%20treatment%20strategies.%20To%20this%20aim%2C%20we%20first%20derive%20the%20asymptotic%20of%20a%20three-species%20slow-fast%20model%20and%20obtain%20a%20two-species%20dynamical%20system%2C%20where%20the%20variables%20are%20tumor%20cells%20and%20infected%20tumor%20cells.%20We%20fully%20characterize%20the%20behavior%20of%20this%20system%20depending%20on%20the%20various%20biological%20parameters.%20In%20the%20second%20part%2C%20we%20address%20the%20modeling%20of%20virus%20injection%20and%20its%20expression%20in%20the%20two-species%20system%2C%20where%20the%20amount%20of%20virus%20does%20not%20appear%20explicitly.%20We%20prove%20that%20the%20injection%20can%20be%20described%20by%20an%20instantaneous%20jump%20in%20the%20phase%20plane%2C%20where%20a%20certain%20amount%20of%20tumors%20cells%20are%20transformed%20instantly%20into%20infected%20tumor%20cells.%20This%20description%20allows%20discussing%20qualitatively%20the%20timing%20of%20different%20injections%20in%20the%20frame%20of%20successive%20treatment%20strategies.%20This%20work%20is%20illustrated%20by%20numerical%20simulations.%20The%20timing%20and%20amount%20of%20injected%20virus%20may%20have%20counterintuitive%20optimal%20values%3B%20nevertheless%2C%20the%20understanding%20is%20clear%20from%20the%20phase%20space%20analysis.%22%2C%22date%22%3A%222022-05-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs11538-022-01025-3%22%2C%22ISSN%22%3A%221522-9602%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A11%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22TVXZQEJ4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bery%20and%20Rabbitts%22%2C%22parsedDate%22%3A%222022-02-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBery%2C%20Nicolas%2C%20and%20Terry%20H.%20Rabbitts.%20%26%23x201C%3BA%20Cell-Based%20Screening%20Method%20Using%20an%20Intracellular%20Antibody%20for%20Discovering%20Small%20Molecules%20Targeting%20Hard-to-Drug%20Proteins.%26%23x201D%3B%20%3Ci%3EBio-Protocol%3C%5C%2Fi%3E%2012%2C%20no.%204%20%28February%2020%2C%202022%29%3A%20e4324.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21769%5C%2FBioProtoc.4324%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21769%5C%2FBioProtoc.4324%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Cell-based%20Screening%20Method%20Using%20an%20Intracellular%20Antibody%20for%20Discovering%20Small%20Molecules%20Targeting%20Hard-to-drug%20Proteins%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Bery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%20H.%22%2C%22lastName%22%3A%22Rabbitts%22%7D%5D%2C%22abstractNote%22%3A%22Targeting%20hard-to-drug%20proteins%2C%20such%20as%20proteins%20functioning%20by%20protein-protein%20interactions%20%28PPIs%29%20with%20small%20molecules%2C%20is%20difficult%20because%20of%20the%20lack%20of%20well-defined%20pockets.%20Fragment%20or%20computational-based%20methods%20are%20usually%20employed%20for%20the%20discovery%20of%20such%20compounds%2C%20but%20no%20generic%20method%20is%20available%20to%20quickly%20identify%20small%20molecules%20interfering%20with%20PPIs.%20Here%2C%20we%20provide%20a%20protocol%20describing%20a%20generic%20method%20to%20discover%20small%20molecules%20inhibiting%20the%20interaction%20between%20an%20intracellular%20antibody%20and%20its%20target%2C%20in%20particular%20for%20proteins%20that%20are%20hard%20to%20make%20in%20recombinant%20form.%20This%20protocol%20reports%20a%20versatile%20and%20generic%20method%20that%20can%20be%20applied%20to%20any%20target%5C%2Fintracellular%20antibody.%20Because%20it%20is%20a%20cell-based%20assay%2C%20it%20identifies%20chemical%20matters%20that%20are%20already%20displaying%20advantageous%20cell%20permeability%20properties.%20Graphic%20abstract%3A%20Cell-based%20intracellular%20antibody-guided%20small%20molecule%20screening.%22%2C%22date%22%3A%222022-02-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.21769%5C%2FBioProtoc.4324%22%2C%22ISSN%22%3A%222331-8325%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A05Z%22%7D%7D%2C%7B%22key%22%3A%229ETGTKME%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Buscail%22%2C%22parsedDate%22%3A%222022-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBuscail%2C%20Louis.%20%26%23x201C%3B%5BPancreatic%20tumors%3A%20a%20hierarchical%20diagnostic%20and%20therapeutic%5D.%26%23x201D%3B%20%3Ci%3ELa%20Revue%20Du%20Praticien%3C%5C%2Fi%3E%2072%2C%20no.%202%20%28February%202022%29%3A%20210.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BPancreatic%20tumors%3A%20a%20hierarchical%20diagnostic%20and%20therapeutic%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-02%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%222101-017X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A11%3A24Z%22%7D%7D%2C%7B%22key%22%3A%224H9PH99J%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rouanet%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERouanet%2C%20Marie%2C%20Naima%20Hanoun%2C%20Hubert%20Lulka%2C%20Cindy%20Ferreira%2C%20Pierre%20Garcin%2C%20Martin%20Sramek%2C%20Godefroy%20Jacquemin%2C%20et%20al.%20%26%23x201C%3BThe%20Antitumoral%20Activity%20of%20TLR7%20Ligands%20Is%20Corrupted%20by%20the%20Microenvironment%20of%20Pancreatic%20Tumors.%26%23x201D%3B%20%3Ci%3EMolecular%20Therapy%3C%5C%2Fi%3E%2C%20January%202022%2C%20S1525001622000181.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ymthe.2022.01.018%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ymthe.2022.01.018%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20antitumoral%20activity%20of%20TLR7%20ligands%20is%20corrupted%20by%20the%20microenvironment%20of%20pancreatic%20tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Rouanet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naima%22%2C%22lastName%22%3A%22Hanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Lulka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cindy%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Garcin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Sramek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Godefroy%22%2C%22lastName%22%3A%22Jacquemin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Pagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Sarot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%22%2C%22lastName%22%3A%22Pancaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ymthe.2022.01.018%22%2C%22ISSN%22%3A%2215250016%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1525001622000181%22%2C%22collections%22%3A%5B%226BDVTCJV%22%2C%226FNA338P%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A10%3A35Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Quillien, Lorraine, Louis Buscail, and Pierre Cordelier. “Pancreatic Cancer Cell and Gene Biotherapies; Past, Present and Future.” Human Gene Therapy<\/i>, December 31, 2022. https:\/\/doi.org\/10.1089\/hum.2022.210<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Chaves-Almagro, Carline, Johanna Auriau, Alizée Dortignac, Pascal Clerc, Hubert Lulka, Simon Deleruyelle, Fabrice Projetti, et al. “Upregulated Apelin Signaling in Pancreatic Cancer Activates Oncogenic Signaling Pathways to Promote Tumor Development.” International Journal of Molecular Sciences<\/i> 23, no. 18 (September 13, 2022): 10600. https:\/\/doi.org\/10.3390\/ijms231810600<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Keller, Laura, Claudine Tardy, Laetitia Ligat, Soazig Le Pennec, Nicolas Bery, Faten Koraïchi, Patrick Chinestra, et al. “Tripartite Split-GFP Assay to Identify Selective Intracellular Nanobody That Suppresses GTPase RHOA Subfamily Downstream Signaling.” Frontiers in Immunology<\/i> 13 (August 18, 2022): 980539. https:\/\/doi.org\/10.3389\/fimmu.2022.980539<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Sorbara, Marie, Pierre Cordelier, and Nicolas Bery. “Antibody-Based Approaches to Target Pancreatic Tumours.” Antibodies<\/i> 11, no. 3 (July 12, 2022): 47. https:\/\/doi.org\/10.3390\/antib11030047<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cordelier, Pierre, Manon Costa, and Jérôme Fehrenbach. “Slow-Fast Model and Therapy Optimization for Oncolytic Treatment of Tumors.” Bulletin of Mathematical Biology<\/i> 84, no. 6 (May 10, 2022): 64. https:\/\/doi.org\/10.1007\/s11538-022-01025-3<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bery, Nicolas, and Terry H. Rabbitts. “A Cell-Based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-Drug Proteins.” Bio-Protocol<\/i> 12, no. 4 (February 20, 2022): e4324. https:\/\/doi.org\/10.21769\/BioProtoc.4324<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Buscail, Louis. “[Pancreatic tumors: a hierarchical diagnostic and therapeutic].” La Revue Du Praticien<\/i> 72, no. 2 (February 2022): 210.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Rouanet, Marie, Naima Hanoun, Hubert Lulka, Cindy Ferreira, Pierre Garcin, Martin Sramek, Godefroy Jacquemin, et al. “The Antitumoral Activity of TLR7 Ligands Is Corrupted by the Microenvironment of Pancreatic Tumors.” Molecular Therapy<\/i>, January 2022, S1525001622000181. https:\/\/doi.org\/10.1016\/j.ymthe.2022.01.018<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2021″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t6BDVTCJV<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2021<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 42742<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-7dcd4f1ed40cc9b0faaf81e3086493c1%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22WI6AFAKQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marinho%20et%20al.%22%2C%22parsedDate%22%3A%222021-12-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMarinho%2C%20Anthony%2C%20Nicolas%20Zalay%2C%20L%26%23xE9%3Bonor%20Chaltiel%2C%20Sylvain%20Kirzin%2C%20Antoine%20Philis%2C%20Jannick%20Selves%2C%20Nicolas%20Carr%26%23xE8%3Bre%2C%20Etienne%20Buscail%2C%20and%20Laurent%20Ghouti.%20%26%23x201C%3BOncologic%20and%20Functional%20Outcomes%20of%20Pelvic%20Perineal%20Reconstruction%20by%20Perineal%20Colostomy%20and%20Malone%20Procedure%20After%20Abdominoperineal%20Resection.%26%23x201D%3B%20%3Ci%3EDiseases%20of%20the%20Colon%20and%20Rectum%3C%5C%2Fi%3E%2064%2C%20no.%2012%20%28December%201%2C%202021%29%3A%201501%26%23x2013%3B10.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FDCR.0000000000001941%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FDCR.0000000000001941%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Oncologic%20and%20Functional%20Outcomes%20of%20Pelvic%20Perineal%20Reconstruction%20by%20Perineal%20Colostomy%20and%20Malone%20Procedure%20After%20Abdominoperineal%20Resection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Marinho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Zalay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9onor%22%2C%22lastName%22%3A%22Chaltiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Kirzin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Philis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jannick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Carr%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Ghouti%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Abdominoperineal%20resection%20is%20the%20standard%20curative%20surgical%20technique%20for%20locally%20advanced%20adenocarcinoma%20of%20the%20lower%20rectum%20and%20squamous%20cell%20carcinoma%20of%20the%20anal%20canal%20after%20chemoradiotherapy.%20However%2C%20it%20requires%20a%20definitive%20abdominal%20colostomy%20that%20modifies%20the%20body%20appearance.%5CnOBJECTIVE%3A%20The%20study%20aim%20was%20to%20evaluate%20the%20combination%20of%20abdominoperineal%20resection%20with%20perineal%20colostomy%20reconstruction%20and%20Malone%20antegrade%20continence%20enema.%5CnDESIGN%3A%20This%20was%20a%20retrospective%20study.%5CnSETTINGS%3A%20The%20study%20was%20conducted%20at%20the%20Toulouse%20Hospital%20Digestive%20Surgery%20Department.%5CnPATIENTS%3A%20All%20of%20the%20patients%20with%20advanced%20adenocarcinoma%20or%20squamous%20cell%20carcinoma%20who%20underwent%20abdominoperineal%20resection%20with%20perineal%20colostomy%20reconstruction%20and%20Malone%20antegrade%20continence%20enema%20%28n%20%3D%2080%29%20between%20December%201999%20and%20December%202016%20were%20included.%5CnMAIN%20OUTCOME%20MEASURES%3A%20The%20main%20outcome%20was%20the%205-year%20overall%20survival%20rate.%5CnRESULTS%3A%20The%205-year%20overall%20survival%20was%2074.89%25%20%2895%25%20CI%2C%2062.91%25-83.50%25%29%2C%20and%20the%20median%20recurrence-free%20survival%20was%20107.6%20months%20%2895%25%20CI%2C%2065.1-198.1%20mo%29.%20The%20median%20follow-up%20was%2091.0%20months%20%2895%25%20CI%2C%2070.4-116.6%20mo%29.%20R0%20resection%20was%20obtained%20in%2064%20patients%20%2880.0%25%29.%20The%20median%20Cleveland%20Clinic%20Incontinence%20Score%20%28to%20assess%20the%20functional%20outcomes%29%20was%209.0%20%28interquartile%20range%2C%201.0-18.0%29%2C%20and%20it%20was%20lower%20in%20patients%20with%20advanced%20adenocarcinoma%20than%20with%20squamous%20cell%20carcinoma%20%287.0%20%28interquartile%20range%2C%202.0-18.0%29%20vs%2011.0%20%28interquartile%20range%2C%201.0-17.0%29%3B%20p%20%3D%200.01%29.%20Eleven%20patients%20%2813.8%25%29%20reported%20perineal%20stains%20during%20the%20night%2C%20and%2019%20patients%20%2823.8%25%29%20needed%20drugs%20to%20reduce%20colon%20motility.%20The%20rate%20of%20severe%20complications%20%28Clavien-Dindo%20%3EII%29%20was%2011.7%25%20%28n%20%3D%209%29.%20Definitive%20colostomy%20was%20performed%20in%2015%20patients%20%2818.8%25%29.%5CnLIMITATIONS%3A%20This%20retrospective%20study%20included%20a%20small%20number%20of%20patients%20from%20a%20single%20center.%20Moreover%2C%20the%20functional%20outcome%20was%20tested%20with%20self-report%20questionnaires%20%28risk%20of%20response%20bias%29.%5CnCONCLUSIONS%3A%20This%20study%20suggests%20that%20abdominoperineal%20resection%20associated%20with%20perineal%20reconstruction%20by%20perineal%20colostomy%20and%20Malone%20antegrade%20continence%20enema%20is%20safe%20and%20may%20improve%20patient%20quality%20of%20life.%20See%20Video%20Abstract%20at%20http%3A%5C%2F%5C%2Flinks.lww.com%5C%2FDCR%5C%2FB629.%5CnRESULTADOS%20ONCOLGICOS%20Y%20FUNCIONALES%20DE%20LA%20RECONSTRUCCIN%20PLVIPERINEAL%20MEDIANTE%20COLOSTOMA%20PERINEAL%20Y%20PROCEDIMIENTO%20DE%20MALONE%20DESPUS%20DE%20LA%20RESECCIN%20ABDOMINOPERINEAL%3A%20ANTECEDENTES%3ALa%20resecci%5Cu00f3n%20abdominoperineal%20es%20la%20t%5Cu00e9cnica%20quir%5Cu00fargica%20curativa%20est%5Cu00e1ndar%20para%20el%20tratamiento%20del%20adenocarcinoma%20localmente%20avanzado%20del%20recto%20inferior%20y%20el%20carcinoma%20a%20c%5Cu00e9lulas%20escamosas%20del%20canal%20anal%2C%20despu%5Cu00e9s%20de%20radio-quimioterapia.%20Sin%20embargo%2C%20requiere%20una%20colostom%5Cu00eda%20abdominal%20definitiva%20que%20modifica%20la%20apariencia%20corporal.OBJETIVO%3AEl%20prop%5Cu00f3sito%20del%20presente%20estudio%20fue%20el%20evaluar%20la%20combinaci%5Cu00f3n%20de%20la%20resecci%5Cu00f3n%20abdominoperineal%20con%20la%20confecci%5Cu00f3n%20de%20una%20colostom%5Cu00eda%20perineal%20asociada%20a%20enemas%20de%20continencia%20anter%5Cu00f3grada%20seg%5Cu00fan%20Malone.DISE%5Cu00d1O%3AEstudio%20retrospectivo.AJUSTES%3AServicio%20de%20Cirug%5Cu00eda%20Digestiva%20del%20Hospital%20de%20Toulouse%2C%20Francia.PACIENTES%3ASe%20incluyeron%20todos%20los%20pacientes%20con%20adenocarcinoma%20avanzado%20o%20carcinoma%20de%20c%5Cu00e9lulas%20escamosas%20que%20se%20sometieron%20a%20resecci%5Cu00f3n%20abdominoperineal%20con%20la%20confecci%5Cu00f3n%20de%20una%20colostom%5Cu00eda%20perineal%20asociada%20a%20enemas%20de%20continencia%20anter%5Cu00f3grada%20seg%5Cu00fan%20Malone%20%28n%20%3D%2080%29%20entre%20diciembre%20de%201999%20y%20diciembre%20de%202016.PRINCIPALES%20MEDIDAS%20DE%20RESULTADO%3AEl%20principal%20resultado%20fue%20la%20tasa%20de%20sobrevida%20global%20a%205%20a%5Cu00f1os.RESULTADOS%3ALa%20sobrevida%20global%20a%205%20a%5Cu00f1os%20fue%20de%2074%2C89%25%20%28IC%20del%2095%25%2C%2062%2C91%20a%2083%2C50%29%20y%20la%20mediana%20de%20supervivencia%20libre%20de%20recurrencia%20fue%20de%20107%2C6%20meses%20%28IC%20del%2095%25%2C%2065%2C1%20a%20198%2C1%29.%20La%20mediana%20de%20seguimiento%20fue%20de%2091%2C0%20meses%20%28IC%20del%2095%25%2C%2070%2C4-116%2C6%29.%20La%20resecci%5Cu00f3n%20R0%20se%20obtuvo%20en%2064%20pacientes%20%2880%2C0%25%29.%20La%20mediana%20de%20puntuaci%5Cu00f3n%20de%20la%20escala%20de%20incontinencia%20de%20la%20Cleveland%20Clinic%20%28para%20evaluar%20los%20resultados%20funcionales%29%20fue%20de%209%2C0%20%5B1%2C0%3B%2018%2C0%5D%2C%20y%20fue%20menor%20en%20pacientes%20con%20adenocarcinoma%20avanzado%20que%20con%20carcinoma%20de%20c%5Cu00e9lulas%20escamosas%20%287%2C0%20%5B2%2C0%3B%2018%2C0%5D%20versus%2011%2C0%20%5B1%2C0%3B%2017%2C0%5D%3B%20p%20%3D%200%2C01%29.%20Once%20pacientes%20%2813%2C8%25%29%20refirieron%20manchado%20perineal%20nocurno%20y%2019%20pacientes%20%2823%2C8%25%29%20necesitaron%20f%5Cu00e1rmacos%20para%20reducir%20la%20motilidad%20del%20colon.%20La%20tasa%20de%20complicaciones%20graves%20%28Clavien-Dindo%20%3E%20II%29%20fue%20del%2011%2C7%25%20%28n%20%3D%209%29.%20Se%20realiz%5Cu00f3%20colostom%5Cu00eda%20definitiva%20en%2015%20%2818%2C8%25%29%20pacientes.LIMITACIONES%3AEste%20estudio%20retrospectivo%20incluy%5Cu00f3%20un%20peque%5Cu00f1o%20n%5Cu00famero%20de%20pacientes%20y%20de%20un%20solo%20centro.%20Adem%5Cu00e1s%2C%20el%20resultado%20funcional%20se%20prob%5Cu00f3%20con%20cuestionarios%20de%20autoinforme%20%28riesgo%20de%20sesgo%20de%20respuesta%29.CONCLUSIONES%3AEste%20estudio%20sugiere%20que%20la%20resecci%5Cu00f3n%20abdominoperineal%20asociada%20con%20la%20confecci%5Cu00f3n%20de%20una%20colostom%5Cu00eda%20perineal%20asociada%20a%20enemas%20de%20continencia%20anter%5Cu00f3grada%20seg%5Cu00fan%20Malone%20es%20segura%20y%20puede%20mejorar%20la%20calidad%20de%20vida%20de%20los%20pacientes.%20Consulte%20Video%20Resumen%20en%20http%3A%5C%2F%5C%2Flinks.lww.com%5C%2FDCR%5C%2FB629.%22%2C%22date%22%3A%222021-12-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FDCR.0000000000001941%22%2C%22ISSN%22%3A%221530-0358%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222022-01-14T16%3A05%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22ZDW2TDXG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sorbara%20and%20Bery%22%2C%22parsedDate%22%3A%222021-11-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESorbara%2C%20Marie%2C%20and%20Nicolas%20Bery.%20%26%23x201C%3BTargeting%20Small%20GTPases%20and%20Their%20Downstream%20Pathways%20with%20Intracellular%20Macromolecule%20Binders%20to%20Define%20Alternative%20Therapeutic%20Strategies%20in%20Cancer.%26%23x201D%3B%20%3Ci%3EBiochemical%20Society%20Transactions%3C%5C%2Fi%3E%2049%2C%20no.%205%20%28November%201%2C%202021%29%3A%202021%26%23x2013%3B35.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1042%5C%2FBST20201059%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1042%5C%2FBST20201059%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Targeting%20small%20GTPases%20and%20their%20downstream%20pathways%20with%20intracellular%20macromolecule%20binders%20to%20define%20alternative%20therapeutic%20strategies%20in%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Sorbara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Bery%22%7D%5D%2C%22abstractNote%22%3A%22The%20RAS%20superfamily%20of%20small%20GTPases%20regulates%20major%20physiological%20cellular%20processes.%20Mutation%20or%20deregulation%20of%20these%20small%20GTPases%2C%20their%20regulators%20and%5C%2For%20their%20effectors%20are%20associated%20with%20many%20diseases%20including%20cancer.%20Hence%2C%20targeting%20these%20classes%20of%20proteins%20is%20an%20important%20therapeutic%20strategy%20in%20cancer.%20This%20has%20been%20recently%20achieved%20with%20the%20approval%20of%20the%20first%20KRASG12C%20covalent%20inhibitors%20for%20the%20clinic.%20However%2C%20many%20other%20mutants%20and%20small%20GTPases%20are%20still%20considered%20as%20%27undruggable%27%20with%20small%20molecule%20inhibitors%20because%20of%20a%20lack%20of%20well-defined%20pocket%28s%29%20at%20their%20surface.%20Therefore%2C%20alternative%20therapeutic%20strategies%20have%20been%20developed%20to%20target%20these%20proteins.%20In%20this%20review%2C%20we%20discuss%20the%20use%20of%20intracellular%20antibodies%20and%20derivatives%20-%20reagents%20that%20bind%20their%20antigen%20inside%20the%20cells%20-%20for%20the%20discovery%20of%20novel%20inhibitory%20mechanisms%2C%20targetable%20features%20and%20therapeutic%20strategies%20to%20inhibit%20small%20GTPases%20and%20their%20downstream%20pathways.%20These%20reagents%20are%20also%20versatile%20tools%20used%20to%20better%20understand%20the%20biological%20mechanisms%20regulated%20by%20small%20GTPases%20and%20to%20accelerate%20the%20drug%20discovery%20process.%22%2C%22date%22%3A%222021-11-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1042%5C%2FBST20201059%22%2C%22ISSN%22%3A%221470-8752%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222022-01-14T16%3A01%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22DVSUXVHZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thibault%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-07%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EThibault%2C%20Benoit%2C%20Fernanda%20Ramos-Delgado%2C%20Elvire%20Pons-Tostivint%2C%20Nicole%20Therville%2C%20Celia%20Cintas%2C%20Silvia%20Arcucci%2C%20Stephanie%20Cassant-Sourdy%2C%20et%20al.%20%26%23x201C%3BPancreatic%20Cancer%20Intrinsic%20PI3K%26%23x3B1%3B%20Activity%20Accelerates%20Metastasis%20and%20Rewires%20Macrophage%20Component.%26%23x201D%3B%20%3Ci%3EEMBO%20Molecular%20Medicine%3C%5C%2Fi%3E%2013%2C%20no.%207%20%28July%207%2C%202021%29%3A%20e13502.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.15252%5C%2Femmm.202013502%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.15252%5C%2Femmm.202013502%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pancreatic%20cancer%20intrinsic%20PI3K%5Cu03b1%20activity%20accelerates%20metastasis%20and%20rewires%20macrophage%20component%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Thibault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Ramos-Delgado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elvire%22%2C%22lastName%22%3A%22Pons-Tostivint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Therville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celia%22%2C%22lastName%22%3A%22Cintas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Arcucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Cassant-Sourdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Reyes-Castellanos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amelie%20V.%22%2C%22lastName%22%3A%22Villard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coralie%22%2C%22lastName%22%3A%22Cayron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Baer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Bertrand-Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Pagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dina%22%2C%22lastName%22%3A%22Ferreira%20Da%20Mota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hongkai%22%2C%22lastName%22%3A%22Yan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chiara%22%2C%22lastName%22%3A%22Falcomat%5Cu00e0%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Muscari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ezra%22%2C%22lastName%22%3A%22Aksoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Carrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dieter%22%2C%22lastName%22%3A%22Saur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Basset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Guillermet-Guibert%22%7D%5D%2C%22abstractNote%22%3A%22Pancreatic%20ductal%20adenocarcinoma%20%28PDAC%29%20patients%20frequently%20suffer%20from%20undetected%20micro-metastatic%20disease.%20This%20clinical%20situation%20would%20greatly%20benefit%20from%20additional%20investigation.%20Therefore%2C%20we%20set%20out%20to%20identify%20key%20signalling%20events%20that%20drive%20metastatic%20evolution%20from%20the%20pancreas.%20We%20searched%20for%20a%20gene%20signature%20that%20discriminate%20localised%20PDAC%20from%20confirmed%20metastatic%20PDAC%20and%20devised%20a%20preclinical%20protocol%20using%20circulating%20cell-free%20DNA%20%28cfDNA%29%20as%20an%20early%20biomarker%20of%20micro-metastatic%20disease%20to%20validate%20the%20identification%20of%20key%20signalling%20events.%20An%20unbiased%20approach%20identified%2C%20amongst%20actionable%20markers%20of%20disease%20progression%2C%20the%20PI3K%20pathway%20and%20a%20distinctive%20PI3K%5Cu03b1%20activation%20signature%20as%20predictive%20of%20PDAC%20aggressiveness%20and%20prognosis.%20Pharmacological%20or%20tumour-restricted%20genetic%20PI3K%5Cu03b1-selective%20inhibition%20prevented%20macro-metastatic%20evolution%20by%20hindering%20tumoural%20cell%20migratory%20behaviour%20independently%20of%20genetic%20alterations.%20We%20found%20that%20PI3K%5Cu03b1%20inhibition%20altered%20the%20quantity%20and%20the%20species%20composition%20of%20the%20produced%20lipid%20second%20messenger%20PIP3%20%2C%20with%20a%20selective%20decrease%20of%20C36%3A2%20PI-3%2C4%2C5-P3%20.%20Tumoural%20PI3K%5Cu03b1%20inactivation%20prevented%20the%20accumulation%20of%20pro-tumoural%20CD206-positive%20macrophages%20in%20the%20tumour-adjacent%20tissue.%20Tumour%20cell-intrinsic%20PI3K%5Cu03b1%20promotes%20pro-metastatic%20features%20that%20could%20be%20pharmacologically%20targeted%20to%20delay%20macro-metastatic%20evolution.%22%2C%22date%22%3A%222021-07-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.15252%5C%2Femmm.202013502%22%2C%22ISSN%22%3A%221757-4684%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22PKLPPQDF%22%2C%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A27%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22M9MWJMJD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMontfort%2C%20Anne%2C%20Florie%20Bertrand%2C%20Julia%20Rochotte%2C%20Julia%20Gilhodes%2C%20Thomas%20Filleron%2C%20Jean%20Milh%26%23xE8%3Bs%2C%20Carine%20Dufau%2C%20et%20al.%20%26%23x201C%3BNeutral%20Sphingomyelinase%202%20Heightens%20Anti-Melanoma%20Immune%20Responses%20and%20Anti-PD-1%20Therapy%20Efficacy.%26%23x201D%3B%20%3Ci%3ECancer%20Immunology%20Research%3C%5C%2Fi%3E%209%2C%20no.%205%20%28May%202021%29%3A%20568%26%23x2013%3B82.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-20-0342%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-20-0342%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neutral%20Sphingomyelinase%202%20Heightens%20Anti-Melanoma%20Immune%20Responses%20and%20Anti-PD-1%20Therapy%20Efficacy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florie%22%2C%22lastName%22%3A%22Bertrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Rochotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Milh%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Imbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00eblle%22%2C%22lastName%22%3A%22Riond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20J.%22%2C%22lastName%22%3A%22Clarke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrei%20A.%22%2C%22lastName%22%3A%22Constantinescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nilton%20De%20Fran%5Cu00e7a%22%2C%22lastName%22%3A%22Junior%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Record%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rochaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Silvente-Poirot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Therville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yusuf%20A.%22%2C%22lastName%22%3A%22Hannun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Benoist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Micheau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22Dysregulation%20of%20lipid%20metabolism%20affects%20the%20behavior%20of%20cancer%20cells%2C%20but%20how%20this%20happens%20is%20not%20completely%20understood.%20Neutral%20sphingomyelinase%202%20%28nSMase2%29%2C%20encoded%20by%20SMPD3%2C%20catalyzes%20the%20breakdown%20of%20sphingomyelin%20to%20produce%20the%20anti-oncometabolite%20ceramide.%20We%20found%20that%20this%20enzyme%20was%20often%20downregulated%20in%20human%20metastatic%20melanoma%2C%20likely%20contributing%20to%20immune%20escape.%20Overexpression%20of%20nSMase2%20in%20mouse%20melanoma%20reduced%20tumor%20growth%20in%20syngeneic%20wild-type%20but%20not%20CD8-deficient%20mice.%20In%20wild-type%20mice%2C%20nSMase2-overexpressing%20tumors%20showed%20accumulation%20of%20both%20ceramide%20and%20CD8%2B%20tumor-infiltrating%20lymphocytes%2C%20and%20this%20was%20associated%20with%20increased%20level%20of%20transcripts%20encoding%20IFN%5Cu03b3%20and%20CXCL9.%20Overexpressing%20the%20catalytically%20inactive%20nSMase2%20failed%20to%20alter%20tumor%20growth%2C%20indicating%20that%20the%20deleterious%20effect%20nSMase2%20has%20on%20melanoma%20growth%20depends%20on%20its%20enzymatic%20activity.%20In%20vitro%2C%20small%20extracellular%20vesicles%20from%20melanoma%20cells%20overexpressing%20wild-type%20nSMase2%20augmented%20the%20expression%20of%20IL12%2C%20CXCL9%2C%20and%20CCL19%20by%20bone%20marrow-derived%20dendritic%20cells%2C%20suggesting%20that%20melanoma%20nSMase2%20triggers%20T%20helper%201%20%28Th1%29%20polarization%20in%20the%20earliest%20stages%20of%20the%20immune%20response.%20Most%20importantly%2C%20overexpression%20of%20wild-type%20nSMase2%20increased%20anti-PD-1%20efficacy%20in%20murine%20models%20of%20melanoma%20and%20breast%20cancer%2C%20and%20this%20was%20associated%20with%20an%20enhanced%20Th1%20response.%20Therefore%2C%20increasing%20SMPD3%20expression%20in%20melanoma%20may%20serve%20as%20an%20original%20therapeutic%20strategy%20to%20potentiate%20Th1%20polarization%20and%20CD8%2B%20T-cell-dependent%20immune%20responses%20and%20overcome%20resistance%20to%20anti-PD-1.%22%2C%22date%22%3A%222021-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F2326-6066.CIR-20-0342%22%2C%22ISSN%22%3A%222326-6074%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%2C%22S3JJUU84%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-06-16T13%3A47%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22JWBJDAVD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tijunelyte%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETijunelyte%2C%20Inga%2C%20R%26%23xE9%3Bmi%20Malbec%2C%20Bayan%20Chami%2C%20Jean%20Cacheux%2C%20Christophe%20Dez%2C%20Thierry%20Leichl%26%23xE9%3B%2C%20Pierre%20Cordelier%2C%20and%20Aur%26%23xE9%3Blien%20Bancaud.%20%26%23x201C%3BMicro-RNA%2021%20Detection%20with%20a%20Limit%20of%202%20PM%20in%201%26%23xA0%3BMin%20Using%20a%20Size-Accordable%20Concentration%20Module%20Operated%20by%20Electrohydrodynamic%20Actuation.%26%23x201D%3B%20%3Ci%3EBiosensors%20%26amp%3B%20Bioelectronics%3C%5C%2Fi%3E%20178%20%28April%2015%2C%202021%29%3A%20112992.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bios.2021.112992%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bios.2021.112992%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22micro-RNA%2021%20detection%20with%20a%20limit%20of%202%20pM%20in%201%5Cu00a0min%20using%20a%20size-accordable%20concentration%20module%20operated%20by%20electrohydrodynamic%20actuation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inga%22%2C%22lastName%22%3A%22Tijunelyte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9mi%22%2C%22lastName%22%3A%22Malbec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bayan%22%2C%22lastName%22%3A%22Chami%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Cacheux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Dez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Leichl%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Bancaud%22%7D%5D%2C%22abstractNote%22%3A%22We%20present%20a%20fluorimetry-based%20technology%20for%20micro-RNA-21%20%28miR-21%29%20sensing%20based%20on%20the%20concentration%20of%20miR-molecular%20beacon%20%28MB%29%20complexes%20and%20flushing%20of%20unbound%20MB.%20This%20concentration%20module%20consists%20of%20a%20microfluidic%20channel%20with%20the%20shape%20of%20a%20funnel%20operated%20with%20electrohydrodynamic%20actuation.%20We%20report%20a%20limit%20of%20detection%20of%202%20pM%20in%20less%20than%201%5Cu00a0min%20for%20miR-21%20alone%2C%20and%20then%20demonstrate%20that%20miR-21%20levels%2C%20measured%20in%20fine%20needle%20biopsy%20samples%2C%20from%20patients%20with%20pancreatic%20cancer%20correlate%20with%20the%20reference%20technique%20of%20reverse-transcription%20polymerase%20chain%20reaction%20%28RT-PCR%29.%20Altogether%2C%20this%20technology%20has%20promising%20clinical%20performances%20for%20the%20follow-up%20of%20patients%20with%20cancer.%22%2C%22date%22%3A%222021-04-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bios.2021.112992%22%2C%22ISSN%22%3A%221873-4235%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-06-16T12%3A19%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22LILYZNQ3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Quillien%20et%20al.%22%2C%22parsedDate%22%3A%222021-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EQuillien%2C%20Lorraine%2C%20Sokunthea%20Top%2C%20Sandrine%20Kappler-Gratias%2C%20Agathe%20Redout%26%23xE9%3B%2C%20Nelson%20Dusetti%2C%20Charlotte%20Quentin-Froignant%2C%20Hubert%20Lulka%2C%20et%20al.%20%26%23x201C%3BA%20Novel%20Imaging%20Approach%20for%20Single-Cell%20Real-Time%20Analysis%20of%20Oncolytic%20Virus%20Replication%20and%20Efficacy%20in%20Cancer%20Cells.%26%23x201D%3B%20%3Ci%3EHuman%20Gene%20Therapy%3C%5C%2Fi%3E%2032%2C%20no.%203%26%23x2013%3B4%20%28February%202021%29%3A%20166%26%23x2013%3B77.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fhum.2020.294%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fhum.2020.294%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Novel%20Imaging%20Approach%20for%20Single-Cell%20Real-Time%20Analysis%20of%20Oncolytic%20Virus%20Replication%20and%20Efficacy%20in%20Cancer%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorraine%22%2C%22lastName%22%3A%22Quillien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sokunthea%22%2C%22lastName%22%3A%22Top%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Kappler-Gratias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agathe%22%2C%22lastName%22%3A%22Redout%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelson%22%2C%22lastName%22%3A%22Dusetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Quentin-Froignant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Lulka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Camus-Bouclainville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Gallardo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Bertagnoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%5D%2C%22abstractNote%22%3A%22Oncolytic%20viruses%20%28OVs%29%20are%20novel%20cancer%20gene%20therapies%20that%20are%20moving%20toward%20the%20forefront%20of%20modern%20medicines.%20However%2C%20their%20full%20therapeutic%20potential%20is%20hindered%20by%20the%20lack%20of%20convenient%20and%20reliable%20strategies%20to%20visualize%20and%20quantify%20OV%20growth%20kinetics%20and%20therapeutic%20efficacy%20in%20live%20cells.%20In%20this%20study%2C%20we%20present%20an%20innovative%20imaging%20approach%20for%20single-cell%20real-time%20analysis%20of%20OV%20replication%20and%20efficacy%20in%20cancer%20cells.%20We%20selected%20SG33%20as%20a%20prototypic%20new%20OV%20that%20derives%20from%20wild-type%20Myxoma%20virus%20%28MYXV%29.%20Lausanne%20Toulouse%201%20%28T1%29%20was%20used%20as%20control.%20We%20equipped%20SG33%20and%20T1%20genomes%20with%20the%20ANCHOR%20system%20and%20infected%20a%20panel%20of%20cell%20lines.%20The%20ANCHOR%20system%20is%20composed%20of%20a%20fusion%20protein%20%28OR-GFP%29%20that%20specifically%20binds%20to%20a%20short%20nonrepetitive%20DNA%20target%20sequence%20%28ANCH%29%20and%20spreads%20onto%20neighboring%20sequences%20by%20protein%20oligomerization.%20Its%20accumulation%20on%20the%20tagged%20viral%20DNA%20results%20in%20the%20creation%20of%20fluorescent%20foci.%20We%20found%20that%20%281%29%20SG33%20and%20T1-ANCHOR%20DNA%20can%20be%20readily%20detected%20and%20quantified%20by%20live%20imaging%2C%20%282%29%20both%20OVs%20generate%20perinuclear%20replication%20foci%20after%20infection%20clustering%20into%20horse-shoe%20shape%20replication%20centers%2C%20and%20%283%29%20SG33%20replicates%20to%20higher%20levels%20as%20compared%20with%20T1.%20Lastly%2C%20as%20a%20translational%20proof%20of%20concept%2C%20we%20benchmarked%20SG33%20replication%20and%20oncolytic%20efficacy%20in%20primary%20cancer%20cells%20derived%20from%20pancreatic%20adenocarcinoma%20%28PDAC%29%20both%20at%20the%20population%20and%20at%20the%20single-cell%20levels.%20In%20vivo%2C%20SG33%20significantly%20replicates%20in%20experimental%20tumors%20to%20inhibit%20tumor%20growth.%20Collectively%2C%20we%20provide%20herein%20for%20the%20first%20time%20a%20novel%20strategy%20to%20quantify%20each%20step%20of%20OV%20infection%20in%20live%20cells%20and%20in%20real%20time%20by%20tracking%20viral%20DNA%20and%20provide%20first%20evidence%20of%20theranostic%20strategies%20for%20PDAC%20patients.%20Thus%2C%20this%20approach%20has%20the%20potential%20to%20rationalize%20the%20use%20of%20OVs%20for%20the%20benefit%20of%20patients%20with%20incurable%20diseases.%22%2C%22date%22%3A%222021-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2Fhum.2020.294%22%2C%22ISSN%22%3A%221557-7422%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-06-16T12%3A11%3A31Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Marinho, Anthony, Nicolas Zalay, Léonor Chaltiel, Sylvain Kirzin, Antoine Philis, Jannick Selves, Nicolas Carrère, Etienne Buscail, and Laurent Ghouti. “Oncologic and Functional Outcomes of Pelvic Perineal Reconstruction by Perineal Colostomy and Malone Procedure After Abdominoperineal Resection.” Diseases of the Colon and Rectum<\/i> 64, no. 12 (December 1, 2021): 1501–10. https:\/\/doi.org\/10.1097\/DCR.0000000000001941<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Sorbara, Marie, and Nicolas Bery. “Targeting Small GTPases and Their Downstream Pathways with Intracellular Macromolecule Binders to Define Alternative Therapeutic Strategies in Cancer.” Biochemical Society Transactions<\/i> 49, no. 5 (November 1, 2021): 2021–35. https:\/\/doi.org\/10.1042\/BST20201059<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Thibault, Benoit, Fernanda Ramos-Delgado, Elvire Pons-Tostivint, Nicole Therville, Celia Cintas, Silvia Arcucci, Stephanie Cassant-Sourdy, et al. “Pancreatic Cancer Intrinsic PI3Kα Activity Accelerates Metastasis and Rewires Macrophage Component.” EMBO Molecular Medicine<\/i> 13, no. 7 (July 7, 2021): e13502. https:\/\/doi.org\/10.15252\/emmm.202013502<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Montfort, Anne, Florie Bertrand, Julia Rochotte, Julia Gilhodes, Thomas Filleron, Jean Milhès, Carine Dufau, et al. “Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.” Cancer Immunology Research<\/i> 9, no. 5 (May 2021): 568–82. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0342<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tijunelyte, Inga, Rémi Malbec, Bayan Chami, Jean Cacheux, Christophe Dez, Thierry Leichlé, Pierre Cordelier, and Aurélien Bancaud. “Micro-RNA 21 Detection with a Limit of 2 PM in 1 Min Using a Size-Accordable Concentration Module Operated by Electrohydrodynamic Actuation.” Biosensors & Bioelectronics<\/i> 178 (April 15, 2021): 112992. https:\/\/doi.org\/10.1016\/j.bios.2021.112992<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Quillien, Lorraine, Sokunthea Top, Sandrine Kappler-Gratias, Agathe Redouté, Nelson Dusetti, Charlotte Quentin-Froignant, Hubert Lulka, et al. “A Novel Imaging Approach for Single-Cell Real-Time Analysis of Oncolytic Virus Replication and Efficacy in Cancer Cells.” Human Gene Therapy<\/i> 32, no. 3–4 (February 2021): 166–77. https:\/\/doi.org\/10.1089\/hum.2020.294<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2020″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t6BDVTCJV<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2020<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 42742<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-69b9cd861290ae76a3afe5da1fed1276%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22XVRZMSA6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Frere%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-24%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFrere%2C%20Corinne%2C%20Benjamin%20Crichi%2C%20Barbara%20Bournet%2C%20Cindy%20Canivet%2C%20Nassim%20Ait%20Abdallah%2C%20Louis%20Buscail%2C%20and%20Dominique%20Farge.%20%26%23x201C%3BPrimary%20Thromboprophylaxis%20in%20Ambulatory%20Pancreatic%20Cancer%20Patients%20Receiving%20Chemotherapy%3A%20A%20Systematic%20Review%20and%20Meta-Analysis%20of%20Randomized%20Controlled%20Trials.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2012%2C%20no.%208%20%28July%2024%2C%202020%29%3A%202028.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12082028%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12082028%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Primary%20Thromboprophylaxis%20in%20Ambulatory%20Pancreatic%20Cancer%20Patients%20Receiving%20Chemotherapy%3A%20A%20Systematic%20Review%20and%20Meta-Analysis%20of%20Randomized%20Controlled%20Trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Frere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Crichi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cindy%22%2C%22lastName%22%3A%22Canivet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nassim%20Ait%22%2C%22lastName%22%3A%22Abdallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Farge%22%7D%5D%2C%22abstractNote%22%3A%22Patients%20with%20pancreatic%20cancer%20%28PC%29%20carry%20the%20highest%20risk%20of%20venous%20thromboembolism%20%28VTE%29%20amongst%20all%20cancer%20patients.%20Appropriate%20use%20of%20primary%20thromboprophylaxis%20might%20significantly%20and%20safely%20reduce%20its%20burden.%20We%20performed%20a%20systematic%20review%20of%20published%20studies%20and%20meeting%20abstracts%20using%20MEDLINE%20and%20EMBASE%20through%20July%202020%20to%20evaluate%20the%20efficacy%20and%20safety%20of%20primary%20thromboprophylaxis%20in%20ambulatory%20PC%20patients%20receiving%20chemotherapy.%20The%20Mantel%5Cu2013Haenszel%20random%20effect%20model%20was%20used%20to%20estimate%20the%20pooled%20event-based%20risk%20ratio%20%28RR%29%20and%20the%20pooled%20absolute%20risk%20difference%20%28RD%29%20with%20a%2095%25%20confidence%20interval%20%28CI%29.%20Five%20randomized%20controlled%20studies%20with%201003%20PC%20patients%20were%20included%20in%20this%20meta-analysis.%20Compared%20to%20placebo%2C%20thromboprophylaxis%20significantly%20decreased%20the%20risk%20of%20VTE%20%28pooled%20RR%200.31%2C%2095%25%20CI%200.19%5Cu20130.51%2C%20p%20%3C%200.00001%2C%20I2%20%3D%208%25%3B%20absolute%20RD%20%5Cu22120.08%2C%2095%25%20CI%20%5Cu22120.12%5Cu2013%5Cu22120.05%2C%20p%20%3C%200.00001%2C%20I2%20%3D%200%25%29%2C%20with%20an%20estimated%20number%20needed%20to%20treat%20of%2011.9%20patients%20to%20prevent%20one%20VTE%20event.%20Similar%20reductions%20of%20VTE%20were%20observed%20in%20studies%20with%20parenteral%20%28RR%200.30%2C%2095%25%20CI%200.17%5Cu20130.53%29%20versus%20oral%20anticoagulants%20%28RR%200.37%2C%2095%25%20CI%200.14%5Cu20130.99%29%20and%20in%20studies%20using%20prophylactic%20doses%20of%20anticoagulants%20%28RR%200.34%2C%2095%25%20CI%200.17%5Cu20130.70%29%20versus%20supra-prophylactic%20doses%20of%20anticoagulants%20%28RR%200.27%2C%2095%25%20CI%200.08%5Cu20130.90%29.%20The%20pooled%20RR%20for%20major%20bleeding%20was%201.08%20%2895%25%20CI%200.47%5Cu20132.52%2C%20p%20%3D%200.85%2C%20I2%20%3D%200%25%29%20and%20the%20absolute%20RD%20was%200.00%20%2895%25%20CI%20%5Cu22120.02%5Cu20130.03%2C%20p%20%3D%200.85%2C%20I2%20%3D%200%25%29.%20Evidence%20supports%20a%20net%20clinical%20benefit%20of%20thromboprophylaxis%20in%20ambulatory%20PC%20patients%20receiving%20chemotherapy.%20Adequately%20powered%20randomized%20phase%20III%20studies%20assessing%20the%20most%20effective%20anticoagulant%20and%20the%20optimal%20dose%2C%20schedule%20and%20duration%20of%20thromboprophylaxis%20to%20be%20used%20are%20warranted.%22%2C%22date%22%3A%222020-07-24%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12082028%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F8%5C%2F2028%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22KP8LHTYQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Amintas%20et%20al.%22%2C%22parsedDate%22%3A%222020-04-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAmintas%2C%20Samuel%2C%20Aur%26%23xE9%3Blie%20Bedel%2C%20Fran%26%23xE7%3Bois%20Moreau-Gaudry%2C%20Julian%20Boutin%2C%20Louis%20Buscail%2C%20Jean-Philippe%20Merlio%2C%20V%26%23xE9%3Bronique%20Vendrely%2C%20Sandrine%20Dabernat%2C%20and%20Etienne%20Buscail.%20%26%23x201C%3BCirculating%20Tumor%20Cell%20Clusters%3A%20United%20We%20Stand%20Divided%20We%20Fall.%26%23x201D%3B%20%3Ci%3EInternational%20Journal%20of%20Molecular%20Sciences%3C%5C%2Fi%3E%2021%2C%20no.%207%20%28April%2010%2C%202020%29%3A%20E2653.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms21072653%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms21072653%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Circulating%20Tumor%20Cell%20Clusters%3A%20United%20We%20Stand%20Divided%20We%20Fall%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Amintas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Bedel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Moreau-Gaudry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julian%22%2C%22lastName%22%3A%22Boutin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Merlio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Vendrely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Dabernat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Buscail%22%7D%5D%2C%22abstractNote%22%3A%22The%20presence%20of%20circulating%20tumor%20cells%20%28CTCs%29%20and%20CTC%20clusters%2C%20also%20known%20as%20tumor%20microemboli%2C%20in%20biological%20fluids%20has%20long%20been%20described.%20Intensive%20research%20on%20single%20CTCs%20has%20made%20a%20significant%20contribution%20in%20understanding%20tumor%20invasion%2C%20metastasis%20tropism%2C%20and%20intra-tumor%20heterogeneity.%20Moreover%2C%20their%20being%20minimally%20invasive%20biomarkers%20has%20positioned%20them%20for%20diagnosis%2C%20prognosis%2C%20and%20recurrence%20monitoring%20tools.%20Initially%2C%20CTC%20clusters%20were%20out%20of%20focus%2C%20but%20major%20recent%20advances%20in%20the%20knowledge%20of%20their%20biogenesis%20and%20dissemination%20reposition%20them%20as%20critical%20actors%20in%20the%20pathophysiology%20of%20cancer%2C%20especially%20metastasis.%20Increasing%20evidence%20suggests%20that%20%5C%22united%5C%22%20CTCs%2C%20organized%20in%20clusters%2C%20resist%20better%20and%20carry%20stronger%20metastatic%20capacities%20than%20%5C%22divided%5C%22%20single%20CTCs.%20This%20review%20gathers%20recent%20insight%20on%20CTC%20cluster%20origin%20and%20dissemination.%20We%20will%20focus%20on%20their%20distinct%20molecular%20package%20necessary%20to%20resist%20multiple%20cell%20deaths%20that%20all%20circulating%20cells%20normally%20face.%20We%20will%20describe%20the%20molecular%20basis%20of%20their%20increased%20metastatic%20potential%20as%20compared%20to%20single%20CTCs.%20We%20will%20consider%20their%20clinical%20relevance%20as%20prognostic%20biomarkers.%20Finally%2C%20we%20will%20propose%20future%20directions%20for%20research%20and%20clinical%20applications%20in%20this%20promising%20topic%20in%20cancer.%22%2C%22date%22%3A%222020-04-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fijms21072653%22%2C%22ISSN%22%3A%221422-0067%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-11-10T16%3A30%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22IJTG6QIF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maulat%20et%20al.%22%2C%22parsedDate%22%3A%222020-03-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaulat%2C%20Charlotte%2C%20Cindy%20Canivet%2C%20C%26%23xE9%3Blia%20Touraine%2C%20Sophie%20Gourgou%2C%20Bertrand%20Napoleon%2C%20Laurent%20Palazzo%2C%20Nicolas%20Flori%2C%20et%20al.%20%26%23x201C%3BA%20New%20Score%20to%20Predict%20the%20Resectability%20of%20Pancreatic%20Adenocarcinoma%3A%20The%20BACAP%20Score.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2012%2C%20no.%204%20%28March%2025%2C%202020%29%3A%20783.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12040783%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12040783%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20New%20Score%20to%20Predict%20the%20Resectability%20of%20Pancreatic%20Adenocarcinoma%3A%20The%20BACAP%20Score%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Maulat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cindy%22%2C%22lastName%22%3A%22Canivet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9lia%22%2C%22lastName%22%3A%22Touraine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Gourgou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Napoleon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Palazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Flori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Piessen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Guibert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Truant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Assenat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Muscari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22the%20BACAP%20Consortium%20the%20BACAP%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22Surgery%20remains%20the%20only%20curative%20treatment%20for%20pancreatic%20ductal%20adenocarcinoma%20%28PDAC%29.%20Therefore%2C%20a%20predictive%20score%20for%20resectability%20on%20diagnosis%20is%20needed.%20A%20total%20of%20814%20patients%20were%20included%20between%202014%20and%202017%20from%2015%20centers%20included%20in%20the%20BACAP%20%28the%20national%20Anatomo-Clinical%20Database%20on%20Pancreatic%20Adenocarcinoma%29%20prospective%20cohort.%20Three%20groups%20were%20defined%3A%20resectable%20%28Res%29%2C%20locally%20advanced%20%28LA%29%2C%20and%20metastatic%20%28Met%29.%20Variables%20were%20analyzed%20and%20a%20predictive%20score%20was%20devised.%20Of%20the%20814%20patients%20included%2C%20703%20could%20be%20evaluated%3A%20164%20Res%2C%20266%20LA%2C%20and%20273%20Met.%20The%20median%20ages%20of%20the%20patients%20were%2069%2C%2071%2C%20and%2069%2C%20respectively.%20The%20median%20survival%20times%20were%2021%2C%2015%2C%20and%20nine%20months%2C%20respectively.%20Six%20criteria%20were%20significantly%20associated%20with%20a%20lower%20probability%20of%20resectability%20in%20multivariate%20analysis%3A%20venous%5C%2Farterial%20thrombosis%20%28p%20%3D%200.017%29%2C%20performance%20status%201%20%28p%20%3D%200.032%29%20or%20%5Cu2265%202%20%28p%20%3D%200.010%29%2C%20pain%20%28p%20%3D%200.003%29%2C%20weight%20loss%20%5Cu2265%208%25%20%28p%20%3D%200.019%29%2C%20topography%20of%20the%20tumor%20%28body%5C%2Ftail%29%20%28p%20%3D%200.005%29%2C%20and%20maximal%20tumor%20size%2020%5Cu201333%20mm%20%28p%20%3C%200.013%29%20or%20%3E33%20mm%20%28p%20%3C%200.001%29.%20The%20BACAP%20score%20was%20devised%20using%20these%20criteria%20with%20an%20accuracy%20of%2081.17%25%20and%20an%20area%20under%20the%20receive%20operating%20characteristic%20%28ROC%29%20curve%20of%200.82%20%2895%25%20confidence%20interval%20%28CI%29%3A%200.78%3B%200.86%29.%20The%20presence%20of%20pejorative%20criteria%20or%20a%20BACAP%20score%20%3C%2050%25%20indicates%20that%20further%20investigations%20and%20even%20neoadjuvant%20treatment%20might%20be%20warranted.%20Trial%20registration%3A%20NCT02818829.%22%2C%22date%22%3A%222020-03-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12040783%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F4%5C%2F783%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22QTX2YHI6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Frances%20and%20Cordelier%22%2C%22parsedDate%22%3A%222020-02-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFrances%2C%20Audrey%2C%20and%20Pierre%20Cordelier.%20%26%23x201C%3BThe%20Emerging%20Role%20of%20Cytidine%20Deaminase%20in%20Human%20Diseases%3A%20A%20New%20Opportunity%20for%20Therapy%3F%26%23x201D%3B%20%3Ci%3EMolecular%20Therapy%3A%20The%20Journal%20of%20the%20American%20Society%20of%20Gene%20Therapy%3C%5C%2Fi%3E%2C%20February%205%2C%202020.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ymthe.2019.11.026%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ymthe.2019.11.026%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Emerging%20Role%20of%20Cytidine%20Deaminase%20in%20Human%20Diseases%3A%20A%20New%20Opportunity%20for%20Therapy%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Frances%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%5D%2C%22abstractNote%22%3A%22The%20recycling%20activity%20of%20cytidine%20deaminase%20%28CDA%29%20within%20the%20pyrimidine%20salvage%20pathway%20is%20essential%20to%20DNA%20and%20RNA%20synthesis.%20As%20such%2C%20CDA%20deficiency%20can%20lead%20to%20replicative%20stress%2C%20notably%20in%20Bloom%20syndrome.%20Alternatively%2C%20CDA%20also%20can%20deaminate%20cytidine%20and%20deoxycytidine%20analog-based%20therapies%2C%20such%20as%20gemcitabine.%20Thus%2C%20CDA%20overexpression%20is%20often%20associated%20with%20lower%20systemic%2C%20chemotherapy-related%2C%20adverse%20effects%20but%20also%20with%20resistance%20to%20treatment.%20Considering%20the%20increasing%20interest%20of%20CDA%20in%20cancer%20chemoresistance%2C%20the%20aims%20of%20this%20review%20are%20to%20describe%20CDA%20structure%2C%20regulation%20of%20expression%2C%20and%20activity%2C%20and%20to%20report%20the%20therapeutic%20strategies%20based%20on%20CDA%20expression%20that%20recently%20emerged%20for%20tumor%20treatment.%22%2C%22date%22%3A%22feb%2C%2005%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ymthe.2019.11.026%22%2C%22ISSN%22%3A%221525-0024%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-11-10T16%3A28%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22P6Q7H2DG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Buscail%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-31%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBuscail%2C%20Louis%2C%20Barbara%20Bournet%2C%20and%20Pierre%20Cordelier.%20%26%23x201C%3BRole%20of%20Oncogenic%20KRAS%20in%20the%20Diagnosis%2C%20Prognosis%20and%20Treatment%20of%20Pancreatic%20Cancer.%26%23x201D%3B%20%3Ci%3ENature%20Reviews.%20Gastroenterology%20%26amp%3B%20Hepatology%3C%5C%2Fi%3E%2C%20January%2031%2C%202020.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41575-019-0245-4%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41575-019-0245-4%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Role%20of%20oncogenic%20KRAS%20in%20the%20diagnosis%2C%20prognosis%20and%20treatment%20of%20pancreatic%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%5D%2C%22abstractNote%22%3A%22Pancreatic%20ductal%20adenocarcinoma%20%28PDAC%29%20is%20predicted%20to%20be%20the%20second%20most%20common%20cause%20of%20death%20within%20the%20next%2010%20years.%20The%20prognosis%20for%20this%20disease%20is%20poor%20despite%20diagnostic%20progress%20and%20new%20chemotherapeutic%20regimens.%20The%20oncogenic%20KRAS%20mutation%20is%20the%20major%20event%20in%20pancreatic%20cancer%3B%20it%20confers%20permanent%20activation%20of%20the%20KRAS%20protein%2C%20which%20acts%20as%20a%20molecular%20switch%20to%20activate%20various%20intracellular%20signalling%20pathways%20and%20transcription%20factors%20inducing%20cell%20proliferation%2C%20migration%2C%20transformation%20and%20survival.%20Several%20laboratory%20methods%20have%20been%20developed%20to%20detect%20KRAS%20mutations%20in%20biological%20samples%2C%20including%20digital%20droplet%20PCR%20%28which%20displays%20high%20sensitivity%29.%20Clinical%20studies%20have%20revealed%20that%20a%20KRAS%20mutation%20assay%20in%20fine-needle%20aspiration%20material%20combined%20with%20cytopathology%20increases%20the%20sensitivity%2C%20accuracy%20and%20negative%20predictive%20value%20of%20cytopathology%20for%20a%20positive%20diagnosis%20of%20pancreatic%20cancer.%20In%5Cu00a0addition%2C%20the%20presence%20of%20KRAS%20mutations%20in%20serum%20and%20plasma%20%28liquid%20biopsies%29%20correlates%20with%5Cu00a0a%20worse%20prognosis.%20The%20presence%20of%20mutated%20KRAS%20can%20also%20have%20therapeutic%20implications%2C%20whether%20at%20the%20gene%20level%20per%20se%2C%20during%20its%20post-translational%20maturation%2C%20interaction%20with%20nucleotides%20and%20after%20activation%20of%20the%20various%20oncogenic%20signals.%20Further%20pharmacokinetic%20and%20toxicological%20studies%20on%20new%20molecules%20are%20required%2C%20especially%20small%20synthetic%20molecules%2C%20before%20they%20can%20be%20used%20in%20the%20therapeutic%20arsenal%20for%20pancreatic%20ductal%20adenocarcinoma.%22%2C%22date%22%3A%22Jan%2031%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41575-019-0245-4%22%2C%22ISSN%22%3A%221759-5053%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A07Z%22%7D%7D%2C%7B%22key%22%3A%2284LQRE26%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Larrieu%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELarrieu%2C%20D.%2C%20M.%20Brunet%2C%20C.%20Vargas%2C%20N.%20Hanoun%2C%20L.%20Ligat%2C%20L.%20Dagnon%2C%20H.%20Lulka%2C%20et%20al.%20%26%23x201C%3BThe%20E3%20Ubiquitin%20Ligase%20TRIP12%20Participates%20in%20Cell%20Cycle%20Progression%20and%20Chromosome%20Stability.%26%23x201D%3B%20%3Ci%3EScientific%20Reports%3C%5C%2Fi%3E%2010%2C%20no.%201%20%28January%2021%2C%202020%29%3A%20789.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-57762-9%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-57762-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20E3%20ubiquitin%20ligase%20TRIP12%20participates%20in%20cell%20cycle%20progression%20and%20chromosome%20stability%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Larrieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Brunet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Vargas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Hanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Ligat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Dagnon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Lulka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20M.%22%2C%22lastName%22%3A%22Pommier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22J%5Cu00e1dy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Bartholin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Torrisani%22%7D%5D%2C%22abstractNote%22%3A%22Several%20studies%20have%20linked%20the%20E3%20ubiquitin%20ligase%20TRIP12%20%28Thyroid%20hormone%20Receptor%20Interacting%20Protein%2012%29%20to%20the%20cell%20cycle.%20However%2C%20the%20regulation%20and%20the%20implication%20of%20this%20protein%20during%20the%20cell%20cycle%20are%20largely%20unknown.%20In%20this%20study%2C%20we%20show%20that%20TRIP12%20expression%20is%20regulated%20during%20the%20cell%20cycle%2C%20which%20correlates%20with%20its%20nuclear%20localization.%20We%20identify%20an%20euchromatin-binding%20function%20of%20TRIP12%20mediated%20by%20a%20N-terminal%20intrinsically%20disordered%20region.%20We%20demonstrate%20the%20functional%20implication%20of%20TRIP12%20in%20the%20mitotic%20entry%20by%20controlling%20the%20duration%20of%20DNA%20replication%20that%20is%20independent%20from%20its%20catalytic%20activity.%20We%20also%20show%20the%20requirement%20of%20TRIP12%20in%20the%20mitotic%20progression%20and%20chromosome%20stability.%20Altogether%2C%20our%20findings%20show%20that%20TRIP12%20is%20as%20a%20new%20chromatin-associated%20protein%20with%20several%20implications%20in%20the%20cell%20cycle%20progression%20and%20in%20the%20maintenance%20of%20genome%20integrity.%22%2C%22date%22%3A%22Jan%2021%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-020-57762-9%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A11Z%22%7D%7D%2C%7B%22key%22%3A%222DS3GGDR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lumeau%20and%20Cordelier%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELumeau%2C%20Audrey%2C%20and%20Pierre%20Cordelier.%20%26%23x201C%3BOne%20Two%20Punch%3A%20Combination%20Chemotherapy%20Knocks%20Out%20Pancreatic%20Cancer.%26%23x201D%3B%20%3Ci%3EMolecular%20Therapy%3C%5C%2Fi%3E%2028%2C%20no.%208%20%282020%29%3A%201751%26%23x2013%3B52.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ymthe.2020.07.014%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ymthe.2020.07.014%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22One%20Two%20Punch%3A%20Combination%20Chemotherapy%20Knocks%20Out%20Pancreatic%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Lumeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2208%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ymthe.2020.07.014%22%2C%22ISSN%22%3A%2215250016%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1525001620303658%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A15Z%22%7D%7D%2C%7B%22key%22%3A%224UIFIZLG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nicolle%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ENicolle%2C%20R%26%23xE9%3Bmy%2C%20Yuna%20Blum%2C%20Pauline%20Duconseil%2C%20Charles%20Vanbrugghe%2C%20Nicolas%20Brandone%2C%20Flora%20Poizat%2C%20Julie%20Roques%2C%20et%20al.%20%26%23x201C%3BEstablishment%20of%20a%20Pancreatic%20Adenocarcinoma%20Molecular%20Gradient%20%28PAMG%29%20That%20Predicts%20the%20Clinical%20Outcome%20of%20Pancreatic%20Cancer.%26%23x201D%3B%20%3Ci%3EEBioMedicine%3C%5C%2Fi%3E%2057%20%282020%29%3A%20102858.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ebiom.2020.102858%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ebiom.2020.102858%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Establishment%20of%20a%20pancreatic%20adenocarcinoma%20molecular%20gradient%20%28PAMG%29%20that%20predicts%20the%20clinical%20outcome%20of%20pancreatic%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Nicolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuna%22%2C%22lastName%22%3A%22Blum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Duconseil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Vanbrugghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Brandone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flora%22%2C%22lastName%22%3A%22Poizat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Roques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Bigonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Gayet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Rubis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nabila%22%2C%22lastName%22%3A%22Elarouci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Armenoult%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mira%22%2C%22lastName%22%3A%22Ayadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22de%20Reyni%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Giovannini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Grandval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephane%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cindy%22%2C%22lastName%22%3A%22Canivet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Cros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Moutardier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Gilabert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Iovanna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelson%22%2C%22lastName%22%3A%22Dusetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2207%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ebiom.2020.102858%22%2C%22ISSN%22%3A%2223523964%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2352396420302334%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A17Z%22%7D%7D%2C%7B%22key%22%3A%226B28YNAR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Frere%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFrere%2C%20Corinne%2C%20Barbara%20Bournet%2C%20Sophie%20Gourgou%2C%20Julien%20Fraisse%2C%20Cindy%20Canivet%2C%20Jean%20M.%20Connors%2C%20Louis%20Buscail%2C%20et%20al.%20%26%23x201C%3BIncidence%20of%20Venous%20Thromboembolism%20in%20Patients%20With%20Newly%20Diagnosed%20Pancreatic%20Cancer%20and%20Factors%20Associated%20With%20Outcomes.%26%23x201D%3B%20%3Ci%3EGastroenterology%3C%5C%2Fi%3E%20158%2C%20no.%205%20%282020%29%3A%201346-1358.e4.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1053%5C%2Fj.gastro.2019.12.009%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1053%5C%2Fj.gastro.2019.12.009%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Incidence%20of%20Venous%20Thromboembolism%20in%20Patients%20With%20Newly%20Diagnosed%20Pancreatic%20Cancer%20and%20Factors%20Associated%20With%20Outcomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Frere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Gourgou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Fraisse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cindy%22%2C%22lastName%22%3A%22Canivet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20M.%22%2C%22lastName%22%3A%22Connors%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Farge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cindy%22%2C%22lastName%22%3A%22Canivet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Carr%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Muscari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Suc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosine%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Couteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Deslandres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Rivera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Pascale%22%2C%22lastName%22%3A%22Laurenty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadim%22%2C%22lastName%22%3A%22Fares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl%22%2C%22lastName%22%3A%22Barange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Napol%5Cu00e9on%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Pujol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Fumex%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Desrame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Lepilliez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodica%22%2C%22lastName%22%3A%22Gincul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Artru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Clavel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Isabelle%22%2C%22lastName%22%3A%22Lemaistre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Palazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Cros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Tubiana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Flori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Senesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Emmanuel%22%2C%22lastName%22%3A%22Colombo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Samail-Scalzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Portales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Gourgou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%20Honfo%22%2C%22lastName%22%3A%22Ga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Plassot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Fraisse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Bibeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Ychou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Guibert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%20de%20la%22%2C%22lastName%22%3A%22Fouchardi%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Sarabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Peyrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9verine%22%2C%22lastName%22%3A%22Tabone-Eglinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Renard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Piessen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Truant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Saudemont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Millet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Renaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leteurtre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Gele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Assenat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Fabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois-R%5Cu00e9gis%22%2C%22lastName%22%3A%22Souche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Dupuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Marie%22%2C%22lastName%22%3A%22Gorce-Dupuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%22%2C%22lastName%22%3A%22Ramos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Seitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Hardwigsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Norguet-Monnereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Grandval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Duluc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Vendrely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Subtil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Terrebonne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Blanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Merlio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Farge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Gornet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Geromin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffroy%22%2C%22lastName%22%3A%22Vanbiervliet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Claire%22%2C%22lastName%22%3A%22Frin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Ouvrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Saint-Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Berthel%5Cu00e9my%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chelbabi%22%2C%22lastName%22%3A%22Fouad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Lesavre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Gasmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Barthet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Cottet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyrille%22%2C%22lastName%22%3A%22Delpierre%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2204%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1053%5C%2Fj.gastro.2019.12.009%22%2C%22ISSN%22%3A%2200165085%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0016508519419215%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A29%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22QGHKHBRF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Amintas%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A6%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAmintas%2C%20Samuel%2C%20V%26%23xE9%3Bronique%20Vendrely%2C%20Charles%20Dupin%2C%20Louis%20Buscail%2C%20Christophe%20Laurent%2C%20Barbara%20Bournet%2C%20Jean-Philippe%20Merlio%2C%20et%20al.%20%26%23x201C%3BNext-Generation%20Cancer%20Biomarkers%3A%20Extracellular%20Vesicle%20DNA%20as%20a%20Circulating%20Surrogate%20of%20Tumor%20DNA.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Cell%20and%20Developmental%20Biology%3C%5C%2Fi%3E%208%20%282020%29%3A%20622048.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcell.2020.622048%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcell.2020.622048%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Next-Generation%20Cancer%20Biomarkers%3A%20Extracellular%20Vesicle%20DNA%20as%20a%20Circulating%20Surrogate%20of%20Tumor%20DNA%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Amintas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Vendrely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Dupin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Merlio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Bedel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Moreau-Gaudry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julian%22%2C%22lastName%22%3A%22Boutin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Dabernat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Buscail%22%7D%5D%2C%22abstractNote%22%3A%22Extracellular%20vesicles%20%28EVs%29%20are%20produced%20by%20healthy%20tissues%20and%20tumor%20cells%20and%20are%20released%20in%20various%20bodily%20fluids%2C%20including%20blood.%20They%20are%20limited%20by%20bilayer%20phospholipidic%20membranes%2C%20and%20they%20carry%20a%20rich%20content%20in%20biomolecules.%20Their%20release%20cleanses%20the%20cells%20of%20their%20waste%20or%20serves%20as%20functional%20local%20and%20distant%20cell-cell%20communication%20and%20molecular%20exchange%20particles.%20This%20rich%20and%20heterogeneous%20content%20has%20been%20given%20intense%20attention%20in%20cancer%20physiopathology%20because%20EVs%20support%20cancer%20control%20and%20progression.%20Because%20of%20their%20specific%20active%20cargo%2C%20they%20are%20being%20evaluated%20as%20carriers%20of%20liquid%20biopsy%20biomarkers.%20Compared%20to%20soluble%20circulating%20biomarkers%2C%20their%20complexity%20might%20provide%20rich%20information%20on%20tumor%20and%20metastases%20status.%20Thanks%20to%20the%20acquired%20genomic%20changes%20commonly%20observed%20in%20oncogenic%20processes%2C%20double-stranded%20DNA%20%28dsDNA%29%20in%20EVs%20might%20be%20the%20latest%20most%20promising%20biomarker%20of%20tumor%20presence%20and%20complexity.%20This%20review%20will%20focus%20on%20the%20recent%20knowledge%20on%20the%20DNA%20inclusion%20in%20vesicles%2C%20the%20technical%20aspects%20of%20EV-DNA%20detection%20and%20quantification%2C%20and%20the%20use%20of%20EV-DNA%20as%20a%20clinical%20biomarker.%22%2C%22date%22%3A%222020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffcell.2020.622048%22%2C%22ISSN%22%3A%222296-634X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-11-10T16%3A30%3A16Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Frere, Corinne, Benjamin Crichi, Barbara Bournet, Cindy Canivet, Nassim Ait Abdallah, Louis Buscail, and Dominique Farge. “Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Cancers<\/i> 12, no. 8 (July 24, 2020): 2028. https:\/\/doi.org\/10.3390\/cancers12082028<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Amintas, Samuel, Aurélie Bedel, François Moreau-Gaudry, Julian Boutin, Louis Buscail, Jean-Philippe Merlio, Véronique Vendrely, Sandrine Dabernat, and Etienne Buscail. “Circulating Tumor Cell Clusters: United We Stand Divided We Fall.” International Journal of Molecular Sciences<\/i> 21, no. 7 (April 10, 2020): E2653. https:\/\/doi.org\/10.3390\/ijms21072653<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Maulat, Charlotte, Cindy Canivet, Célia Touraine, Sophie Gourgou, Bertrand Napoleon, Laurent Palazzo, Nicolas Flori, et al. “A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score.” Cancers<\/i> 12, no. 4 (March 25, 2020): 783. https:\/\/doi.org\/10.3390\/cancers12040783<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Frances, Audrey, and Pierre Cordelier. “The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?” Molecular Therapy: The Journal of the American Society of Gene Therapy<\/i>, February 5, 2020. https:\/\/doi.org\/10.1016\/j.ymthe.2019.11.026<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Buscail, Louis, Barbara Bournet, and Pierre Cordelier. “Role of Oncogenic KRAS in the Diagnosis, Prognosis and Treatment of Pancreatic Cancer.” Nature Reviews. Gastroenterology & Hepatology<\/i>, January 31, 2020. https:\/\/doi.org\/10.1038\/s41575-019-0245-4<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Larrieu, D., M. Brunet, C. Vargas, N. Hanoun, L. Ligat, L. Dagnon, H. Lulka, et al. “The E3 Ubiquitin Ligase TRIP12 Participates in Cell Cycle Progression and Chromosome Stability.” Scientific Reports<\/i> 10, no. 1 (January 21, 2020): 789. https:\/\/doi.org\/10.1038\/s41598-020-57762-9<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lumeau, Audrey, and Pierre Cordelier. “One Two Punch: Combination Chemotherapy Knocks Out Pancreatic Cancer.” Molecular Therapy<\/i> 28, no. 8 (2020): 1751–52. https:\/\/doi.org\/10.1016\/j.ymthe.2020.07.014<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Nicolle, Rémy, Yuna Blum, Pauline Duconseil, Charles Vanbrugghe, Nicolas Brandone, Flora Poizat, Julie Roques, et al. “Establishment of a Pancreatic Adenocarcinoma Molecular Gradient (PAMG) That Predicts the Clinical Outcome of Pancreatic Cancer.” EBioMedicine<\/i> 57 (2020): 102858. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102858<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Frere, Corinne, Barbara Bournet, Sophie Gourgou, Julien Fraisse, Cindy Canivet, Jean M. Connors, Louis Buscail, et al. “Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes.” Gastroenterology<\/i> 158, no. 5 (2020): 1346-1358.e4. https:\/\/doi.org\/10.1053\/j.gastro.2019.12.009<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Amintas, Samuel, Véronique Vendrely, Charles Dupin, Louis Buscail, Christophe Laurent, Barbara Bournet, Jean-Philippe Merlio, et al. “Next-Generation Cancer Biomarkers: Extracellular Vesicle DNA as a Circulating Surrogate of Tumor DNA.” Frontiers in Cell and Developmental Biology<\/i> 8 (2020): 622048. https:\/\/doi.org\/10.3389\/fcell.2020.622048<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2019″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t6BDVTCJV<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2019<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 42742<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-0ed142dd4012b194721375a89dc5f85a%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%225NUHPEHL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Diaz-Riascos%20et%20al.%22%2C%22parsedDate%22%3A%222019-06-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDiaz-Riascos%2C%20Zamira%20Vanessa%2C%20Mireia%20M.%20Ginesta%2C%20Joan%20Fabregat%2C%20Teresa%20Serrano%2C%20Juli%20Busquets%2C%20Louis%20Buscail%2C%20Pierre%20Cordelier%2C%20and%20Gabriel%20Capell%26%23xE1%3B.%20%26%23x201C%3BExpression%20and%20Role%20of%20MicroRNAs%20from%20the%20MiR-200%20Family%20in%20the%20Tumor%20Formation%20and%20Metastatic%20Propensity%20of%20Pancreatic%20Cancer.%26%23x201D%3B%20%3Ci%3EMolecular%20Therapy.%20Nucleic%20Acids%3C%5C%2Fi%3E%2017%20%28June%2029%2C%202019%29%3A%20491%26%23x2013%3B503.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.omtn.2019.06.015%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.omtn.2019.06.015%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Expression%20and%20Role%20of%20MicroRNAs%20from%20the%20miR-200%20Family%20in%20the%20Tumor%20Formation%20and%20Metastatic%20Propensity%20of%20Pancreatic%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zamira%20Vanessa%22%2C%22lastName%22%3A%22Diaz-Riascos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mireia%20M.%22%2C%22lastName%22%3A%22Ginesta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan%22%2C%22lastName%22%3A%22Fabregat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Teresa%22%2C%22lastName%22%3A%22Serrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juli%22%2C%22lastName%22%3A%22Busquets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Capell%5Cu00e1%22%7D%5D%2C%22abstractNote%22%3A%22MicroRNAs%20from%20the%20miR-200%20family%20are%20commonly%20associated%20with%20the%20inhibition%20of%20the%20metastatic%20potential%20of%20cancer%20cells%2C%20following%20inhibition%20of%20ZEB%20transcription%20factors%20expression%20and%20epithelial-to-mesenchymal%20transition.%20However%2C%20previous%20studies%20performed%20in%20pancreatic%20adenocarcinoma%20revealed%20a%20more%20complex%20picture%20challenging%20this%20canonical%20model.%20To%20gain%20better%20insights%20into%20the%20role%20of%20miR-200%20family%20members%20in%20this%20disease%2C%20we%20analyzed%20the%20expression%20of%20miR-200a%2C%20miR-200b%2C%20miR-200c%2C%20miR-141%2C%20miR-429%2C%20and%20miR-205%2C%20and%20ZEB1%2C%20ZEB2%2C%20and%20CDH1%20in%20pancreatic%20tumors%20and%20matching%20normal%20adjacent%20parenchyma%20and%20patient-derived%20xenografts.%20We%20found%20that%20miR-200a%2C%20miR-429%2C%20and%20miR-205%20are%20frequently%20overexpressed%20in%20pancreatic%20tumors%2C%20whereas%20CDH1%20is%20downregulated%2C%20and%20ZEB1%20and%20ZEB2%20levels%20remain%20unchanged.%20Furthermore%2C%20we%20measured%20a%20positive%20correlation%20between%20miR-200%20family%20members%20and%20CDH1%20expression%2C%20and%20a%20negative%20correlation%20between%20ZEB1%20and%20miR-200c%2C%20miR-141%2C%20and%20miR-205%20expression%2C%20respectively.%20Interestingly%2C%20we%20identified%20significant%20changes%20in%20expression%20of%20epithelial-to-mesenchymal%20transition%20regulators%20and%20miR-200%20members%20in%20patient-derived%20xenografts.%20Lastly%2C%20functional%20studies%20revealed%20that%20miR-141%20and%20miR-429%20inhibit%20the%20tumorigenic%20potential%20of%20pancreatic%20cancer%20cells.%20Taken%20together%2C%20this%20comprehensive%20analysis%20strongly%20suggests%20that%20miRNAs%20from%20the%20miR-200%20family%2C%20and%20in%20particular%20miR-429%2C%20may%20act%20as%20a%20tumor%20suppressor%20gene%20in%20pancreatic%20cancer.%22%2C%22date%22%3A%22Jun%2029%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.omtn.2019.06.015%22%2C%22ISSN%22%3A%222162-2531%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A28Z%22%7D%7D%2C%7B%22key%22%3A%223RYWQTQ2%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Buscail%20et%20al.%22%2C%22parsedDate%22%3A%222019-06-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBuscail%2C%20Etienne%2C%20Charlotte%20Maulat%2C%20Fabrice%20Muscari%2C%20Laurence%20Chiche%2C%20Pierre%20Cordelier%2C%20Sandrine%20Dabernat%2C%20Catherine%20Alix-Panabi%26%23xE8%3Bres%2C%20and%20Louis%20Buscail.%20%26%23x201C%3BLiquid%20Biopsy%20Approach%20for%20Pancreatic%20Ductal%20Adenocarcinoma.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2011%2C%20no.%206%20%28June%2019%2C%202019%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11060852%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11060852%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Liquid%20Biopsy%20Approach%20for%20Pancreatic%20Ductal%20Adenocarcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Maulat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Muscari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Chiche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Dabernat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Alix-Panabi%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Buscail%22%7D%5D%2C%22abstractNote%22%3A%22Pancreatic%20cancer%20is%20a%20public%20health%20problem%20because%20of%20its%20increasing%20incidence%2C%20the%20absence%20of%20early%20diagnostic%20tools%2C%20and%20its%20aggressiveness.%20Despite%20recent%20progress%20in%20chemotherapy%2C%20the%205-year%20survival%20rate%20remains%20below%205%25.%20Liquid%20biopsies%20are%20of%20particular%20interest%20from%20a%20clinical%20point%20of%20view%20because%20they%20are%20non-invasive%20biomarkers%20released%20by%20primary%20tumours%20and%20metastases%2C%20remotely%20reflecting%20disease%20burden.%20Pilot%20studies%20have%20been%20conducted%20in%20pancreatic%20cancer%20patients%20evaluating%20the%20detection%20of%20circulating%20tumour%20cells%2C%20cell-free%20circulating%20tumour%20DNA%2C%20exosomes%2C%20and%20tumour-educated%20platelets.%20There%20is%20heterogeneity%20between%20the%20methods%20used%20to%20isolate%20circulating%20tumour%20elements%20as%20well%20as%20the%20targets%20used%20for%20their%20identification.%20Performances%20for%20the%20diagnosis%20of%20pancreatic%20cancer%20vary%20depending%20of%20the%20technique%20but%20also%20the%20stage%20of%20the%20disease%3A%2030-50%25%20of%20resectable%20tumours%20are%20positive%20and%2050-100%25%20are%20positive%20in%20locally%20advanced%20and%5C%2For%20metastatic%20cases.%20A%20significant%20prognostic%20value%20is%20demonstrated%20in%2050-70%25%20of%20clinical%20studies%2C%20irrespective%20of%20the%20type%20of%20liquid%20biopsy.%20Large%20prospective%20studies%20of%20homogeneous%20cohorts%20of%20patients%20are%20lacking.%20One%20way%20to%20improve%20diagnostic%20and%20prognostic%20performances%20would%20be%20to%20use%20a%20combined%20technological%20approach%20for%20the%20detection%20of%20circulating%20tumour%20cells%2C%20exosomes%2C%20and%20DNA.%22%2C%22date%22%3A%22Jun%2019%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers11060852%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22KZV4AUIX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dromain%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDromain%2C%20Clarisse%2C%20Marianne%20E.%20Pavel%2C%20Philippe%20Ruszniewski%2C%20Alison%20Langley%2C%20Christine%20Massien%2C%20Eric%20Baudin%2C%20Martyn%20E.%20Caplin%2C%20and%20CLARINET%20Study%20Group.%20%26%23x201C%3BTumor%20Growth%20Rate%20as%20a%20Metric%20of%20Progression%2C%20Response%2C%20and%20Prognosis%20in%20Pancreatic%20and%20Intestinal%20Neuroendocrine%20Tumors.%26%23x201D%3B%20%3Ci%3EBMC%20Cancer%3C%5C%2Fi%3E%2019%2C%20no.%201%20%28January%2014%2C%202019%29%3A%2066.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-018-5257-x%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-018-5257-x%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tumor%20growth%20rate%20as%20a%20metric%20of%20progression%2C%20response%2C%20and%20prognosis%20in%20pancreatic%20and%20intestinal%20neuroendocrine%20tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarisse%22%2C%22lastName%22%3A%22Dromain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marianne%20E.%22%2C%22lastName%22%3A%22Pavel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Ruszniewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alison%22%2C%22lastName%22%3A%22Langley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Massien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Baudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martyn%20E.%22%2C%22lastName%22%3A%22Caplin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CLARINET%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Lanreotide%20depot%5C%2Fautogel%20antitumor%20activity%20in%20intestinal%5C%2Fpancreatic%20neuroendocrine%20tumors%20%28NETs%29%20was%20demonstrated%20in%20the%20phase-3%20CLARINET%20study%20%28NCT00353496%29%2C%20based%20on%20significantly%20prolonged%20progression-free%20survival%20%28PFS%29%20versus%20placebo.%5CnMETHODS%3A%20During%20CLARINET%2C%20patients%20with%20metastatic%20intestinal%5C%2Fpancreatic%20NETs%20received%20lanreotide%20depot%5C%2Fautogel%20120%5Cu2009mg%20or%20placebo%20every%204%5Cu2009weeks%20for%2096%5Cu2009weeks.%20Imaging%20data%20%28response%20evaluation%20criteria%20in%20solid%20tumors%20%5BRECIST%5D%20v1.0%2C%20centrally%20reviewed%29%20were%20re-evaluated%20in%20this%20post%20hoc%20analysis%20of%20tumor%20growth%20rate%20%28TGR%29%20in%20NETs.%20TGR%20%28%25%5C%2Fmonth%29%20was%20calculated%20from%20two%20imaging%20scans%20during%20relevant%20periods%3A%20pre-treatment%20%28TGR0%29%3B%2012-24%5Cu2009weeks%20before%20randomization%20versus%20baseline%3B%20each%20treatment%20visit%20versus%20baseline%20%28TGRTx-0%29%3B%20between%20consecutive%20treatment%20visits%20%28TGRTx-Tx%29.%20To%20assess%20TGR%20as%20a%20measure%20of%20prognosis%2C%20PFS%20was%20compared%20for%20TGR0%20subgroups%20stratified%20by%20optimum%20TGR0%20cut-off%3B%20a%20multivariate%20analysis%20was%20conducted%20to%20identify%20prognostic%20factors%20for%20PFS.%5CnRESULTS%3A%20TGR0%20revealed%20tumors%20growing%20during%20pre-treatment%20%28median%20%5Binterquartile%20range%5D%20TGR0%3A%20lanreotide%202.1%25%5C%2Fmonth%20%5B0.2%3B%206.1%5D%3B%20placebo%202.7%25%5C%2Fmonth%20%5B0.15%3B%206.8%5D%29%2C%20contrary%20to%20RECIST%20status.%20TGR%20was%20significantly%20reduced%20by%2012%5Cu2009weeks%20with%20lanreotide%20versus%20placebo%20%28difference%20in%20least-square%20mean%20TGR0-12%20of%20-%5Cu20092.9%20%5B-%5Cu20095.1%2C%20-%5Cu20090.8%5D%2C%20p%5Cu00a0%3D%5Cu20090.008%29%2C%20a%20difference%20that%20was%20maintained%20at%20most%20subsequent%20visits.%20TGR0%5Cu00a0%3E%5Cu20094%25%5C%2Fmonth%20had%20greater%20risk%20of%20progression%5C%2Fdeath%20than%20%5Cu22644%25%5C%2Fmonth%20%28hazard%20ratio%204.1%3B%20%5B95%25%20CI%202.5-6.5%5D%3B%20p%5Cu00a0%3C%5Cu20090.001%29%3B%20multivariate%20analysis%20revealed%20lanreotide%20treatment%2C%20progression%20at%20baseline%2C%20TGR0%2C%20hepatic%20tumor%20load%2C%20and%20primary%20tumor%20type%20were%20independently%20associated%20with%20PFS.%5CnCONCLUSIONS%3A%20TGR%20provides%20valuable%20information%20on%20tumor%20activity%20and%20prognosis%20in%20patients%20with%20metastatic%20intestinal%5C%2Fpancreatic%20NETs%2C%20and%20identifies%20early%20lanreotide%20depot%5C%2Fautogel%20antitumor%20activity.%5CnTRIAL%20REGISTRATION%3A%20Retrospective%20registration%2C%2018%20July%202006%3B%20EudraCT%3A%202005-004904-35%3B%20ClinicalTrials.gov%3A%20NCT00353496%20.%22%2C%22date%22%3A%22Jan%2014%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-018-5257-x%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22MKSGNASH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cacheux%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECacheux%2C%20Jean%2C%20Aur%26%23xE9%3Blien%20Bancaud%2C%20Thierry%20Leichl%26%23xE9%3B%2C%20and%20Pierre%20Cordelier.%20%26%23x201C%3BTechnological%20Challenges%20and%20Future%20Issues%20for%20the%20Detection%20of%20Circulating%20MicroRNAs%20in%20Patients%20With%20Cancer.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Chemistry%3C%5C%2Fi%3E%207%20%282019%29%3A%20815.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffchem.2019.00815%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffchem.2019.00815%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Technological%20Challenges%20and%20Future%20Issues%20for%20the%20Detection%20of%20Circulating%20MicroRNAs%20in%20Patients%20With%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Cacheux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Bancaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Leichl%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%5D%2C%22abstractNote%22%3A%22In%20the%20era%20of%20precision%20medicine%2C%20the%20success%20of%20clinical%20trials%2C%20notably%20for%20patients%20diagnosed%20with%20cancer%2C%20strongly%20relies%20on%20biomarkers%20with%20pristine%20clinical%20value%20but%20also%20on%20robust%20and%20versatile%20analytical%20technologies%20to%20ensure%20proper%20patients%27%20stratification%20and%20treatment.%20In%20this%20review%2C%20we%20will%20first%20address%20whether%20plasmatic%20and%20salivary%20microRNAs%20can%20be%20considered%20as%20a%20reliable%20source%20of%20biomarkers%20for%20cancer%20diagnosis%20and%20prognosis.%20We%20will%20then%20discuss%20the%20pre-analytical%20steps%20preceding%20miRNA%20quantification%20%28from%20isolation%20to%20purification%29%2C%20and%20how%20such%20process%20could%20be%20biased%20and%20time-consuming.%20Next%2C%20we%20will%20review%20the%20most%20recent%20tools%20derived%20from%20micro-%20and%20nano-technologies%20for%20microRNA%20detection%20available%20to%20date%20and%20how%20they%20may%20compete%20with%20current%20standards.%20This%20review%20will%20prioritize%20publications%20using%20relevant%20biological%20samples.%20The%20significance%20of%20various%20physical%20transduction%20schemes%20%28mechanical%2C%20optical%2C%20electrical%2C%20etc.%29%20for%20biological%20detection%20will%20be%20compared%2C%20and%20pros%20and%20cons%20of%20each%20method%20will%20be%20widely%20discussed.%20Finally%2C%20we%20will%20debate%20on%20how%20micro%20and%20nanotechnologies%20could%20widespread%20the%20use%20of%20biomarkers%20in%20modern%20medicine%2C%20to%20help%20manage%20patients%20with%20serious%20diseases%20such%20as%20cancer.%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffchem.2019.00815%22%2C%22ISSN%22%3A%222296-2646%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A53Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Diaz-Riascos, Zamira Vanessa, Mireia M. Ginesta, Joan Fabregat, Teresa Serrano, Juli Busquets, Louis Buscail, Pierre Cordelier, and Gabriel Capellá. “Expression and Role of MicroRNAs from the MiR-200 Family in the Tumor Formation and Metastatic Propensity of Pancreatic Cancer.” Molecular Therapy. Nucleic Acids<\/i> 17 (June 29, 2019): 491–503. https:\/\/doi.org\/10.1016\/j.omtn.2019.06.015<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Buscail, Etienne, Charlotte Maulat, Fabrice Muscari, Laurence Chiche, Pierre Cordelier, Sandrine Dabernat, Catherine Alix-Panabières, and Louis Buscail. “Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma.” Cancers<\/i> 11, no. 6 (June 19, 2019). https:\/\/doi.org\/10.3390\/cancers11060852<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Dromain, Clarisse, Marianne E. Pavel, Philippe Ruszniewski, Alison Langley, Christine Massien, Eric Baudin, Martyn E. Caplin, and CLARINET Study Group. “Tumor Growth Rate as a Metric of Progression, Response, and Prognosis in Pancreatic and Intestinal Neuroendocrine Tumors.” BMC Cancer<\/i> 19, no. 1 (January 14, 2019): 66. https:\/\/doi.org\/10.1186\/s12885-018-5257-x<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cacheux, Jean, Aurélien Bancaud, Thierry Leichlé, and Pierre Cordelier. “Technological Challenges and Future Issues for the Detection of Circulating MicroRNAs in Patients With Cancer.” Frontiers in Chemistry<\/i> 7 (2019): 815. https:\/\/doi.org\/10.3389\/fchem.2019.00815<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

team members
<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider color=”#F19532″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

\n
<\/div>\n\n\n
\n
\n
\n
\n
\n
\"\"<\/a><\/div>\n
No\u00e9mie Delenclos<\/a><\/div>\n
Master \/ Master student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Margot Cristol<\/a><\/div>\n
Master \/ Master student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Laura Jouvin<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Jean Cacheux<\/a><\/div>\n
Chercheur Post-Doctorant \/ Post-Doc researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Alban Ricard<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Damien Varry<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Sophie Gilbert<\/a><\/div>\n
Chercheur Post-Doctorant \/ Post-Doc researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Barbara Bournet<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Nicolas Carr\u00e8re<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Charlotte Maulat<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Louis Buscail<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Fabrice Muscari<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
J\u00e9r\u00f4me Torrisani<\/a><\/div>\n
Chercheur statutaire \/ permanent scientist<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Nikolaos Kontopoulos<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Pierre Cordelier<\/a><\/div>\n
Chercheur statutaire \/ permanent scientist<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Guillaume Labrousse<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Agathe Redout\u00e9<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Marie Sorbara<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Na\u00efma Hanoun-Ziane<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Nicolas B\u00e9ry<\/a><\/div>\n
Chercheur statutaire \/ permanent scientist<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n <\/div>\n<\/div><\/div>\n\n
\n
<\/div>\n